nykode therapeutics

ANNUAL REPORT 2023

CONTENTS

NYKODE AT A GLANCE

OUR VISION

is to build a leading immunotherapy company developing game changing medicine across an expanding range of therapeutic areas

nykode

173

employees at the end of 2023. Nykode was founded in 2006 and with offices in Oslo and Copenhagen

PLATFORM

biotech company with proprietary immunotherapies targeting antigens to Antigen Presenting Cells and generating strong CD8 T cell responses correlated with clinical responses in solid tumors

MODULAR

and versatile technology that easily incorporates new antigens and adapts to new diseases across oncology, infectious diseases and autoimmunity

STRATEGIC PARTNERSHIPS

to advance clinical programs and commercialize assets worldwide include Regeneron and Genentech, a member of the Roche Group

WELL-CAPITALIZED

with a cash position of USD 162.6 million at December 31, 2023

2023 HIGHLIGHTS

In 2023, Nykode achieved pivotal milestones, most notably the positive Phase 2 trial results of VB10.16 for HPV16-positive malignancies. Additionally, the company secured significant funding through an oversubscribed private placement, attracting international life science specialist investors. These milestones, among others, underscore Nykode's commitment to advancing its oncology pipeline and exploring new therapeutic areas. This progress sets a solid foundation for future success in addressing unmet medical needs.



February
VB-C-04: announced collaboration with the GOG Foundation.

April
VB-C-02: reported positive final results from our Phase 2 trial, demonstrating promising duration and survival data along with a favorable safety profile.

June
VB-C-04: expanded clinical collaboration with Roche, evaluating VB10.16 in combination with atezolizumab in patients with advanced cervical cancer.

July
- VB-C-03: received approvals from the competent authorities in all eight European countries to initiate a Phase 2 trial
- VB-N-02: conducted safety clearance of 9mg dose observing no safety concerns and no dose-limiting toxicities.

September
VB-C-04: received FDA approval of the investigational new drug (IND) application.

September
- Hosted Capital Markets Days in New York and Oslo
- Showcased preclinical data by Regeneron demonstrating potent T cell responses induced by Nykode's APC targeting vaccines.
- Presented compelling preclinical data in autoimmune disease models, opening a new therapeutic vertical for Nykode.

September
VB-C-03: initiated trial in head and neck cancer.

October
Raised USD 45 million in gross proceeds from an oversubscribed private placement.

October
Presented data on mRNA delivery of Vaccibodies, demonstrating they result in faster, broader, and stronger immune responses than non-targeted vaccines, in both DNA and mRNA forms.

December
Expanded oncology pipeline with a preclinical program aimed at reducing the burden of colorectal cancer.

2023 KEY FIGURES

USD '000	2023	2022
Total revenue and other income	13,323	9,029
Total operating expenses	71,405	62,185
Operating profit (loss)	(58,082)	(53,156)
Net profit (loss) for the year	(35,154)	(42,743)
Net cash flow	(44,995)	(9,285)
Cash and cash equivalents, year-end	162,602	206,386
Outstanding shares, year-end	326,546,444	294,694,309
Cash and cash equivalents/ total assets	78%	93%
Equity ratio	82%	71%
Equity	171,259	157,018
Total assets	208,185	221,477
Employees, average	159	132
Employees, year-end	173	155

2024 OUTLOOK AND KEY PRIORITIES

Area	2024 key priorities	Program	Objectives
Oncology	Expand and mature oncology pipeline	VB10.16 and VB10.NEO	VB10.16 • VB-C-02 updated survival data from Ph2 trial • Dose level recommendation for the VB-C-03 trial in head and neck • VB-C-04 trial initiation in U.S. • Finalization of enrollment for Part 1 of the VB-C-04 trial VB10.NEO • Execute on VB-N-02 Phase 1b trial and Genentech collaboration*
		NKY011	Detailed update on preclinical program
		Undisclosed internal- and external programs	Advance and expand early pipeline Execute on Regeneron oncology collaboration*
Autoimmune	Expand and mature autoimmune pipeline	Undisclosed internal program	Deliver update on Nykode's preclinical autoimmune disease program
Technology development	Leverage techno-logy platform within new opportunities		Deliver update on Nykode's APC-targeted vaccine technology delivered by mRNA

* Communications on collaboration projects are controlled by Genentech and Regeneron, respectively.

NYKODE THERAPEUTICS' VACCINE TECHNOLOGY PLATFORM

The Vaccibody™ molecule

Nykode Therapeutic's proprietary, targeted immunotherapy platform centers around the Vaccibody molecule format designed to induce potent, long-lasting and specific immune responses. The specificity of the targeting unit of the Vaccibody molecule determines to which subsets of Antigen Presenting Cells (APC) or cell type the antigen is delivered, which may critically influence the associated immune response.

CCL3L1, C-C motif chemokine ligand 3 like 1, is so far the most used targeting unit in Nykode's vaccine candidates and part of several vaccine candidates undergoing clinical development. CCL3L1 targeted immunotherapies have been shown to have a unique ability to attract and stimulate APC's capable of eliciting broad, strong and dominant CD8 T cell responses combined with supporting CD4 helper T cell responses. CD8 T cell responses are key to killing tumor cells and are also important for controlling infected cells in an infectious disease setting. The unique ability to induce broad and strong T cell responses distinguishes Nykode's platform from both conventional vaccines, including non-targeted DNA vaccines, RNA vaccines and peptide-based vaccines.

Vaccine candidates based on the modular Vaccibody molecule are well tolerated and therefore may have the potential to be used in combination with other therapeutic modalities such as immune checkpoint inhibitors.

The recombinant Vaccibody molecule consists of three core modules with the possibility of adding additional modules:

A The targeting unit directs the antigens to the immune system's APCs. The targeting unit is fully flexible and can be designed to deliver T cell epitopes or antigens specifically to certain subset of APC optimizing the desired effect. This controlled delivery allows for induction of a specific immune response profile that correlates with protection for each specific disease, e.g., antibody, CD4 (Th1/Th2/Th17) and/or CD8 T cell responses; or in the case of tolerizing vaccines, induces proliferation of antigen specific T regulatory cells.

B The dimerization unit joins the two protein chains into the dimeric Vaccibody format. The dimeric format is designed to facilitate attraction, activation and internalization into the APC by crosslinking receptors on the surface of the APC.

C The antigen unit contains the epitopes and antigens selected, to which a specific immune response is warranted. Epitopes and antigens may be selected to address a vast range of diseases, including cancer, infectious diseases and autoimmune diseases. The flexibility of the platform allows for a broad immune response and for inclusion of large globular antigens and multiple sets of T cell epitopes.

D The 4th module is a concept where a 4th (or 5th etc.) module code is inserted into the DNA plasmid in order to co-express immune enhancing, immune inhibiting and/or immune guiding polypeptides. 4th module polypeptides have been shown in preclinical models to have a booster effect in both anti-tumor and infectious disease models, as well as providing enhanced immune-inhibiting effect in an autoimmune disease model.

PIPELINE

Nykode's technology platform may potentially benefit the lives of patients across several disease areas. The ongoing trials cover:

Nykode's lead candidate, wholly owned VB10.16 therapeutic cancer vaccine against HPV16-positive cancers is being evaluated in three trials, one in advanced cervical cancer, one in cancer of the head and neck, and one in locally advanced cervical cancer, for which the protocol is currently in development.

VB10.NEO is an individualized neoantigen cancer vaccine exclusively licensed to Genentech, a member of the Roche Group. It is being evaluated in incurable locally advanced and metastatic tumors.

NYK011 is a preclinical candidate that was recently added to Nykode's pipeline and covers precancerous polyps and colorectal cancer.

Five different programs under the Nykode-Regeneron multi-target license and collaboration agreement to develop innovative vaccines against cancer and infectious diseases are currently in discovery.

Nykode's internal research pipeline covers the areas of oncology and autoimmune diseases.



1. Wholly-owned by Nykode. Potentially registrational. Roche supplies atezolizumab; 2. Wholly-owned by Nykode. Merck (MSD) supplies pembrolizumab; 3. Collaboration with Regeneron; 4. Genentech has an exclusive license to VB10.NEO.
5. Protocol in development.

LETTER TO SHAREHOLDERS

LETTER TO OUR SHAREHOLDERS

Dear shareholders,

As we reflect on the past year, it is with pride that we present the 2023 Annual Report, marking a year of remarkable achievements and milestones for Nykode Therapeutics. Our commitment to pioneering innovative immunotherapy technologies and advancing our oncology pipeline has yielded notable results, setting a new standard in our pursuit of addressing unmet medical needs.

The year was highlighted by the notable success of the VB-C-02 trial, investigating the use of Nykode's therapeutic cancer vaccine candidate VB10.16 in combination with Roche's cancer immunotherapy Tecentriq®[1] (atezolizumab) in patients with advanced or recurrent, non-resectable HPV16-positive cervical cancer, a study made possible through our supply agreement with Roche. The data revealed strong survival rates compared to historical monotherapy data with atezolizumab, alongside a favorable safety profile for the vaccine. These results have laid the foundation for an ambitious development plan to further progress VB10.16 in treating advanced cervical cancer and to extend its application to earlier stage cervical cancer as well as head and neck cancer.

Within cervical cancer we obtained FDA approval for our Investigational New Drug (IND) application for the VB-C-04 clinical trial. This clinical trial is in collaboration with Roche to evaluate VB10.16 in combination with Roche's checkpoint inhibitor, atezolizumab, in HPV16-positive patients with recurrent metastatic cervical cancer. The trial has a potential registrational intent that could pave the way for a rapid market introduction. The study is being conducted in partnership with the GOG Foundation, Inc., leveraging its five decades of experience in advancing new, top-tier treatments for gynecologic cancer patients.

The VB-C-03 trial's initiation, targeting PD-L1 positive, first-line, unresectable, recurrent, or metastatic head and neck cancer with VB10.16 in combination with KEYTRUDA®[2] (pembrolizumab), reaffirms our commitment to expanding our therapeutic spectrum.

[1] Tecentriq® is a registered trademark of the Roche Group.
[2] KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

2023 was a year of remarkable achievements... the notable success of the VB-C-02 trial lays the foundation for an ambitious development plan for VB10.16 in treating advanced cervical cancer and its potential extension to earlier stages and other cancers

Our other lead asset, the individualized immunotherapy program VB10.NEO, which is exclusively licensed to Genentech, a member of the Roche Group, also continued to show progress. We demonstrated sustainable immune responses lasting for at least one year after vaccination. In the N-02 trial the dose was escalated to 9 mg without any safety or toxicity concerns. The aim is to determine the optimal phase 2 dose regimen for continued development of VB10.NEO in combination with atezolizumab.

The collaboration with Regeneron, targeting multiple therapeutic areas, has made significant advances in 2023 and is moving closer to the first lead candidate selection. This partnership leverages our innovative modular immunotherapy platform alongside Regeneron's distinct expertise in antigen selection, encompassing three oncology and two infectious disease programs. We are excited about the prospect of developing transformative medicines with a leading pharmaceutical company.

In September, we hosted Capital Markets Days in New York and Oslo presenting additional data for both VB10.16 and VB10.NEO. It also showcased preclinical data generated by Regeneron demonstrating that Nykode's Antigen Presenting Cell (APC) targeting vaccines induce potent T cell responses. Additionally, Nykode presented compelling preclinical data across different autoimmune disease models, potentially opening a commercially attractive new therapeutic vertical for Nykode.

Financially, we have strengthened our position through an oversubscribed private placement, raising USD 45 million and attracting international blue-chip investors with extensive experience in investing in life science companies. This achievement not only broadens our shareholder base but also reinforces our capacity to innovate and grow.

In the last quarter of the year, we presented compelling data on the mRNA delivery of Vaccibodies, emphasizing the superior immune responses they elicit compared to traditional vaccines. This positions Nykode for considerable growth and expands our potential for partnerships. Moreover, we have expanded our oncology pipeline, targeting colorectal cancer, aiming to address the disease's burden across various stages. This initiative, rooted in our second-generation technology and novel antigen combinations, exemplifies our pursuit of groundbreaking solutions to cancer's most pressing challenges.

Looking ahead, our focus remains on leveraging our unique platform to deliver meaningful benefits to patients. We are deeply grateful to our shareholders, partners, and the Nykode team for their unwavering support and dedication. Together, we are making significant strides towards transforming the landscape of cancer treatment and immunotherapy.

In 2024, our focus will be on operational execution of our promising wholly owned and partnered programs. This includes advancing the VB-C-03 trial towards selecting the dose for Part 2 and ensuring that the VB-C-04 trial is fully operational. We also anticipate sharing further insights into our innovative "inverse vaccine" technology for autoimmune diseases.

Thank you for your continued trust and partnership.

Sincerely,

April 18, 2024

Martin Nicklasson	**Michael Engsig**
Chairman of the Board	CEO

BOARD OF DIRECTORS REPORT

BOARD OF DIRECTORS REPORT

Nykode Therapeutics has experienced a year of significant advancement of its vaccine technology, securing major clinical and strategic milestones. Noteworthy accomplishments include the positive final outcomes in the Phase 2 trial VB-C-02 for VB10.16, targeting heavily pre-treated advanced cervical cancer patients. Furthermore, the company received the FDA's IND approval for clinical trial VB-C-04, commenced the VB-C-03 trial across Europe, and made substantial progress in its collaboration with Regeneron, aiming for the first lead candidate selection. We've also seen very good progress with our fully individualized cancer vaccine VB10.NEO, developed in collaboration with Genentech. The successful clearance of the 9 milligram dose used in patients for the first time without any safety concerns increases confidence in VB10.NEO and other programs.

Our financial standing has been considerably enhanced through a successful USD 45 million private placement, bolstering our strategic initiatives and innovation capacity.

Looking ahead to 2024, Nykode is poised for several advancements in our clinical programs, including the VB-C-03 and VB-C-04 trials, and unveiling our innovative approach in autoimmune disease research through our "inverse vaccine" technology. Our focus remains steadfast on leveraging our platform to revolutionize cancer treatment and immunotherapy, driving forward with operational excellence and strategic growth.

We look forward to updating the patients, shareholders, employees, and other stakeholders on the progress during the year.

RESEARCH AND PRECLINICAL DEVELOPMENT



Nykode is dedicated to discovering and developing next-generation vaccines for cancer and autoimmune diseases by leveraging our unique and proprietary technology that targets Antigen Presenting Cells (APC). This technology has proven to excel in inducing rapid, strong, and broad antigen-specific T cell responses.

Our research and innovation strategy is centered around our commitment to pioneering new ways of coding medicine by breaking down conventional drug design.

To achieve this, we are focused on several key objectives:

- Building and maturing a pipeline of differentiated vaccine candidates within oncology and autoimmune disorders with best-in-class or first-in-class potential.
- Expanding into novel therapeutic areas and novel therapeutic molecules.
- Further developing and improving our APC-targeting technology platform to broaden its applicability.

During 2023, Nykode expanded its discovery pipeline by adding a potential first-in-class preclinical oncology vaccine program aimed at preventing and treating colorectal cancer. Nykode's novel vaccines are based on a careful selection and combination of highly expressed tumor associated antigens involved in the development and progression of colonic polyps to colorectal cancer. Additionally, the program incorporates Nykode's proprietary 4th module second-generation technology to further optimize the immune responses tailored to diverse target populations. Strong preclinical data generated in the discovery phase further supports the induction of potent CD8 T cell responses in both wild-type and HLA transgenic mice models.

The multi-target discovery-phase collaboration with Regeneron, covering five vaccine programs within oncology and infectious diseases, has also made significant progress in 2023. Preclinical data from Regeneron demonstrated that Nykode's APC-targeted technology is effective in breaking tolerance against tumor-associated antigens, including those with low or no thymic expression, thus not typically subject to central tolerance. This highlights the Nykode vaccine platform's potential in targeting a range of self-antigens associated with tumors. These promising findings exemplify some of the many possibilities in Nykode's future vaccine development endeavors beyond viral and individualized neoantigens.

2023 saw an increased focus on building further validation into the tolerizing vaccine platform. Tolerizing vaccines aim to dampen unwanted immune responses, such as seen in autoimmune and allergic disorders, through "inverse" vaccination. Nykode's platform is uniquely positioned to target antigens to tolerizing

dendritic cells (DCs) promoting antigen specific T regulatory (Treg) cell activity.

At the Capital Markets Day in September, Nykode presented new data showing that our vaccines, which target tolerogenic dendritic cells, prevent serious disease in a Multiple Sclerosis (MS)-like mouse disease model. The disease-preventing effect was very potent and demonstrated using different APC-targeting units, further supporting the platform's flexibility. Additionally, Nykode's inverse vaccines targeting tolerogenic DCs demonstrated efficacy in a spontaneous type 1 diabetes mouse model, completely preventing the development of diabetes in the model. Nykode's 4th module cytokine technology was found to further amplify the efficacy of the vaccine. These breakthrough data represent a significant additional commercial opportunity for Nykode, reinforcing its position as industry front-runner.

Nykode is one of the leading companies specializing in APC-targeting vaccines and continues to invest in and maintain a strong focus on further developing and enhancing its technology platform. This effort aims to secure future IP and attract new collaborations across therapeutic areas.

At the annual mRNA Cancer Vaccines Summit in Boston, Massachusetts, Nykode presented preclinical data for the first time, highlighting the differentiating factors of Nykode's proprietary vaccine technology. When delivered either via DNA or mRNA, Nykode's APC-targeted cancer vaccines lead to a faster and broader T cell response compared to standard mRNA vaccines with identical antigens in a head-to-head comparison. These data demonstrate the effectiveness of the APC-targeted vaccine approach in driving superior T cell responses for cancer immunotherapy, whether the vaccine is delivered by DNA or mRNA.

NYKODE DEVELOPMENT PROJECTS

Nykode's development portfolio consists of two oncology programs: VB10.16 and VB10.NEO. The development candidates are designed based on Nykode's Vaccibody technology platform of targeting antigens to Antigen Presenting Cells (APC).

VB10.16

VB10.16 is a potentially first-in-class off-the-shelf therapeutic cancer vaccine candidate in development for the treatment of human papillomavirus type 16 (HPV16)-positive cancers. VB10.16 is wholly owned by Nykode.

During 2023, the Company has shown significant progress in the development of VB10.16. Updated development plans were presented announcing ambitious trials including a U.S. trial in advanced cervical cancer with a potential registrational intent.

In the second quarter 2023, we reported positive final results, demonstrating promising durable tumor control and survival data as well as being tolerated with a favorable safety profile, from our Phase 2 trial, VB-C-02 of VB10.16 in combination with PD-L1 inhibitor Tecentriq®[1] (atezolizumab) in advanced cervical cancer.

The encouraging clinical efficacy and favorable safety profile that was observed with VB10.16 has led the Company to update the development strategy for VB10.16.

Also in the second quarter, we received approvals from the competent authorities in all eight European countries where the trial will be conducted, to initiate the VB-C-03 trial with VB10.16 in combination with KEYTRUDA®[2] (pembrolizumab) for PD-L1 positive, 1st line unresectable recurrent, or metastatic head and neck cancer patients. The trial was subsequently initiated in September.

During the third quarter, we achieved a significant milestone by receiving FDA approval for the Investigational New Drug (IND) application for VB-C-04 (VB10.16) in combination with Roche's checkpoint inhibitor Tecentriq®[1] (atezolizumab) in HPV16-positive recurrent or metastatic cervical cancer patients.

[1] Tecentriq® is a registered trademark of the Roche Group
[2] KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Information on cervical cancer:

Cervical cancer is the fourth leading cause of cancer death in women worldwide and is most frequently diagnosed between the ages of 35 and 44. Each year around 600,000 women are diagnosed with cervical cancer worldwide. Almost all cases are caused by human papillomavirus (HPV) infection and HPV16 accounts for more than half of all cervical cancer cases. Cervical cancer is often curable when detected early and effectively managed, but treatment options are more limited in advanced disease stages or when the cancer has spread.

Source: HPV Information Centre; CDC.gov; Cancer.org; GLOBOCAN

Information on HNSCC:

The number of patients with squamous cell head and neck cancer (HNSCC) has risen substantially during the last decades and around 660,000 patients globally are now diagnosed yearly. This rise in incidence in HNSCC is mainly attributed to Human Papilloma Virus (HPV) infections. HPV16 accounts for nearly 90% of such cases. HNSCC can be managed effectively in early stages, however, most patients are diagnosed at advanced stages where treatment outcomes are less favorable.

Source: HPV Information Centre; CDC.gov; Cancer.org; GLOBOCAN

VB10.NEO

VB10.NEO is an individualized neoantigen vaccine in development for the treatment of locally advanced or metastatic solid tumors under an exclusive, worldwide clinical collaboration with Genentech, a member of the Roche Group. The vaccine is designed to be produced on-demand according to the neoantigen profile of an individual patient.

Neoantigens are proteins generated by tumor-specific mutations not present in normal tissues and are thus an attractive target for cancer immunotherapy as they may be recognized as foreign by the immune system.

In 2023, the VB10.NEO clinical program was advancing with two trials, VB-N-01 and VB-N-02.

Additional data from the VB-N-01 trial were presented in 2023. The data show that VB10.NEO was generally well tolerated in patients with various pre-treated and advanced tumor entities. VB10.NEO induced broad and long-lasting neoantigen specific T cell responses, persisting for at least one year following the administration of the last dose of VB10.NEO, where the majority of the tested neoantigens activated polyfunctional CD8 T cells. The T-cell responses seen were elicited in both TMB (tumor mutational burden) high and low tumors indicating the selection of high quality neoepitopes within different tumor entities. In addition, we saw identical expanded T-cell clones in the tumor as in the blood post-vaccination as a proof-of-concept that vaccine-induced neoantigen-specific T cells in the periphery are able to infiltrate tumors.

Nykode is currently proceeding with VB-N-02 under the VB10.NEO clinical program.

VB-N-02 is an open-label Phase 1b, dose-escalation study of the safety- and antigen-specific immune responses elicited by VB10.NEO in combination with Roche's checkpoint inhibitor atezolizumab in patients with locally advanced and metastatic tumors across more than ten different tumor types (NCT05018273). The trial is the first Nykode trial to test the 9 mg dose and how it will perform in comparison with the 3 mg dose that was used in the earlier VB-N-01 trial. There were no reported safety concerns nor dose-limiting toxicities.



PARTNERSHIPS AND COLLABORATIONS

At Nykode, collaboration with leading and like-minded partners is key to our success and our ambition of breaking the boundaries of medicine. In partners, we look for expertise which may accelerate our programs and for complimentary technologies which may strengthen our platform. The objective is to continuously develop the Company's strategic and competitive position and to optimize the utilization of its technology platform in order to offer better treatments to patients.

In June 2023, Nykode expanded its clinical collaboration with Roche to include the VB-C-04 trial, evaluating VB10.16 in combination with Roche's checkpoint inhibitor atezolizumab in patients with advanced cervical cancer. Under the terms of the agreement, Nykode will sponsor and fund the planned clinical trial, and Roche will provide atezolizumab. Nykode retains all commercial rights to VB10.16 worldwide.



Nykode's external collaborations and drug combinations include:

Company	Year	Agreement type	Nykode program & trial	Indication	Partner compound
Adaptive Biotechnologies	2021	In-license	VB10.2210 / VB-D-01	T cell focused SARS-CoV-2 booster vaccine	-
Genentech	2020	Out-license and collaboration	VB10.NEO / VB-N-01 / VB-N-02	Multiple cancer indications (individualized cancer vaccines)	-
MSD	2022	Product supply	VB10.16 / VB-C-03	Advanced HPV16+ head & neck cancer	Pembrolizumab (KEYTRUDA®)
Nektar Therapeutics	2018	Collaboration and product supply	VB10.NEO / VB-N-01	Advanced head & neck cancer	Bempegal-des-leukin (NKTR-214)
Regeneron	2021	Out-license and collaboration		Oncology and Infectious Disease (multitarget, off-the-shelf vaccines)	-
Roche	2019	Product supply	VB10.16 / VB-C-02 / VB-C-04	Advanced HPV16+ cervical cancer	Atezolizumab (Tecentriq®)

FINANCIAL REVIEW

The financial statements of the Company for the year ended December 31, 2023 have been prepared in accordance with International Financial Reporting Standards (IFRS) as adopted by the European Union (EU). Numbers in brackets are for the corresponding period the previous year unless otherwise specified.

Income statement

The net result for 2023 was a net loss of USD 35.2 million compared to a net loss of USD 42.7 million in 2022.

Operating income
Total revenue and other income amounted to USD 13.3 million compared to USD 9.0 million in 2022, reflecting the increased activities related to the R&D services provided over time under the agreement with Genentech.

Operating expenses
Total operating expenses amounted to USD 71.4 million compared to USD 62.2 million in 2022. Employee benefit expenses were USD 27.5 million (USD 18.0 million). The increase in employee benefit expenses is due to the increased number of employees and a smaller decrease in the social security cost accrual related to share-based payments in 2023. The reduction in the social security cost accrual related to share-based payments during the year ended December 31, 2023 was USD 0.8 million (USD 8.0 million). Other operating expenses decreased from USD 42.3 million in the year ended December 31, 2022 to USD 41.8 million in the year ended December 31, 2023. Other operating expense for 2022 include a non-recurring cost of USD 5.3 million related to an onerous contract for R&D services.

Net financial income and costs
Net financial income and costs were positive USD 14.0 million in the year ended December 31, 2023 (USD 2.2 million positive). Finance income and finance costs mainly relate to interest income, movements in foreign currency exchange rates and interest expense on lease liabilities. Interest income was USD 8.9 million in 2023 (USD 3.7 million), reflecting the increased interest rate levels.

Income tax expenses
The Group recognized tax income of USD 8.9 million compared to USD 8.2 million in 2022. The income tax expense is primarily related to movement in deferred tax.



Statement of financial position

Cash
Cash and cash equivalents amounted to USD 162.6 million at December 31, 2023 compared to USD 206.4 million at December 31, 2022.

Other non-current receivables
Other non-current receivables were USD 31.9 million (USD 0.0 million). The increase mainly reflects the NOK 325 million (USD 29.0 million) payment to the Norwegian Tax Authorities in the fourth quarter of 2023 following their negative decision. Nykode has appealed the decision to the Norwegian Tax Administration (Norw: Skatteklagenemda).

Trade receivables
Trade receivables amounted to USD 0.0 million at December 31, 2023, compared to USD 2.5 million at December 31, 2022.

Equity
Total equity amounted to USD 171.3 million at December 31, 2023, compared to USD 157.0 million at December 31, 2022. The increase reflects the private placement in October 2023 raising gross proceeds of NOK 505.3 million (USD 45 million), the exercise of warrants and recognition of share-based payments, offset by the net loss for the period of USD 35.2 million.

Trade and other payables
Trade and other payables amounted to USD 7.1 million at December 31, 2023, compared to USD 10.2 million at December 31, 2022. The decrease is mainly due to a reduction in accounts payable at the end of 2023 compared to year-end 2022.

Contract liabilities
At December 31, 2023, total contract liability amounted to USD 8.2 million, compared to a contract liability of USD 19.7 million at December 31, 2022. The contract liability is mainly due to timing of invoicing to Genentech as well as recognition of the service component under the Genentech agreement



Cash flow

Net change in cash and cash equivalents was negative USD 45.0 million in the year ended December 31, 2023, compared to USD 9.3 million negative for the same period in 2022.

Cash flow from operating activities
Net cash flow from operating activities was negative USD 96.6 million in the year ended December 31, 2023, compared to USD 20.7 million negative for the same period in 2022. The change was primarily driven by the decrease in trade receivables due to the receipt of a milestone payment from Genentech in the first quarter of 2022 and the payment to the Norwegian Tax Authorities in the fourth quarter of 2023.

Cash flow from investing activities
Cash flow from investing activities was positive USD 7.0 million in the year ended December 31, 2023 (USD 11.1 million positive). The amounts mainly relate to interest received in 2022 and 2023 and the sale of money market funds in 2022, offset by the purchase of property, plant and equipment.

Cash flow from financing activities
Cash flow from financing activities was positive USD 44.6 million in the year ended December 31, 2023 (USD 0.4 million positive), reflecting the private placement in October 2023.

Allocation of the Parent Company's net result

The Board of Directors proposed that the loss of USD 35.2 million in Nykode Therapeutics ASA is transferred to retained earnings

WORKING ENVIRONMENT

People & Organization

Nykode is a company driven by the goal to pioneer and unlock the future of medicine. Being aware of the impact diversity has on financial performance and innovation levels, diversity naturally forms a part of our strategic focus and is deeply rooted in our values. Our core values - courage, integrity, collaboration, respect and flexibility - serve as guiding principles in our efforts to promote equality within our company.

Nykode embraces diversity and strives to foster an environment of mutual respect that builds trust, safety and wellbeing. We value everyone's perspective, accept each person without judgment, and acknowledge the importance of each other's roles. This commitment is evident in our project-driven organization, where team members from diverse backgrounds and areas of expertise join forces to deliver the best possible outcomes.

Nykode's people are essential to the company's ability to deliver on its strategic priorities. Therefore, Nykode aspires to attract, develop, and retain the best talent in the biotechnology sector worldwide. Nykode attracts people from a wide range of expertise, including scientist from the fields of biotechnology and immunology, as well as skilled business developers. The organization grew by 12% during 2023, reaching a total of 173 employees in Norway and Denmark as of December 31, 2023.

As a part of our ongoing efforts to cultivate and enhance our culture, we conducted the first Employee Engagement Survey among all employees of Nykode. The response rate of 98% attests to the dedication of our people and their drive to make Nykode an even better place to work. Nykode and its leaders demonstrate their commitment to improve by conducting workshops throughout the entire organization and developing action plans to further improve our employee engagement.

Equality and anti-discrimination

Nykode prides itself in its people. We are committed to ensuring that all our employees experience inclusion and equality in their daily work life. We work proactively and systematically to promote equality, prevent discrimination based on gender, pregnancy, leave related to childbirth or adoption, care responsibilities, ethnicity, religion, belief, disability, sexual orientation, gender identity, gender expression or combination of these grounds, and aim to prevent harassment, sexual harassment, and gender-based violence.

In our 2023 Employee Engagement Survey, 92% of our employees answered favorably to the statement "People of all different backgrounds, characteristics, and beliefs are welcome here." This reflects our dedication to fostering a caring and diverse culture. According to global statistics and other key HR indicator tables, the composition of the Board of Directors meets the legal requirements for a Norwegian Limited Liability Company, as well as its Nomination Committee and Corporate Governance Charters. The company has initiated specific guidelines on equality and diversity within a "Diversity, Equity and Inclusion" (DE&I) strategy. A DE&I Sounding Board has been formed to guide and improve Nykode's work on DE&I.

The Norwegian Equality and Anti-Discrimination Act Section 26, mandates that employers have a duty to promote equality and prevent discrimination. In accordance with these regulations, Nykode is required to report on the current state of gender equality within the company and outline the measures it is taking to fulfil the obligations under Section 26. Nykode has conducted a gender pay gap review analysis that is outlined in the table below. Nykode had no involuntary part-time work in 2023.

Gender pay gap in the Norwegian part of Nykode as per December 31, 2023

Gender Pay Gap	Women	Men	Women's pay in % of men's pay
Total pay gap between woman and men	96 (70%)	42 (30%)	96%
Level 1 - Senior Management	1 (50%)	1 (50%)	96%
Level 2- Managers below Sr. Management	15 (65%)	8 (35%)	101%
Level 3 - Senior Professionals	31 (63%)	18 (37%)	104%
Level 4 - Professionals	49 (77%)	15 (23%)	96%

The table below presents statistics on the status of gender equality in Nykode as per December 31, 2023.

31.12.2023	Norway			Denmark			Group total		
	Female	**Male**	**Total**	**Female**	**Male**	**Total**	**Female**	**Male**	**Total**
Employees working full time	96	42	138	19	14	33	115	56	171
Employees working part time	2	0	2	0	0	0	2	0	2
Employees on temporary engagements	2	0	2	0	0	0	2	0	2
Total	100	42	142	19	14	33	119	56	175
	70 %	30 %	100 %	58 %	44 %	100 %	68%	32 %	100 %

The average number of weeks of parental leave in 2023 was 19 weeks for women, and 10 weeks for men.

The work related to the duty of activity
Nykode adheres to a global code of conduct that prioritizes the health and safety of its employees. We have established safe whistleblowing procedures, as mandated by Norwegian law, enabling employees to report incidents related to e.g., discrimination, sexual harassment, or other forms of harassment. All employees are informed about their ability to report incidents, with details provided in the employee handbook. This handbook also includes various routines, guidelines and policies related to equality and diversity. The employee handbook is digital and easily accessible by all employees. We continuously update our employee handbooks for Norway and Denmark, incorporating measures that contribute to a work environment fostering diversity and inclusion.

Companies in Norway are required to implement the four-step model outlined in Section 26, second paragraph, or the Equality and Anti-Discrimination Act. During 2023, Nykode has persisted in its efforts to integrate equality and prevent discrimination within the organization across all grounds of discrimination mentioned in Section 26. This includes HR-processes on recruitment, salary and working condition, development opportunities, accommodation and the ability to balance work and family life. The board will regularly review efforts related to gender equality and inclusion. Diversity and inclusion continue to be integral to our culture.

Global statistics on other Key HR indicators per 31.12.2023

	2023	2022
Employees	173	155
Gender Diversity, M/F	32% / 68%	33% / 67%
Employee turn over	13%	8%
Gender diversity Board of Directors, M/F	62% / 38%	62% / 38%



CORPORATE SOCIAL RESPONSIBILITY

Employees
A primary focus of Nykode Therapeutics' corporate social responsibility (CSR) efforts is its employees. The Company has no formal policy on CSR but adheres to a set of guidelines in its Code of Conduct regarding employee health and safety, and conduct towards healthcare professionals, vendors and competitors. The Company has a focus on promoting an overall healthy working environment. For 2023, there was one work-related injury reported which resulted in sick-leave. The sick-leave ratio of absence for 2023 was 2.3%, compared to 1.5% in 2022.

Environmental, social and governance
In 2023, the Company continued its dedication to environmental, social, and governance (ESG) practices, integrating them with its core values of courage, integrity, collaboration, respect and flexibility. It embarked on concrete steps to reduce its environmental footprint, focusing on energy use, greenhouse gas emissions, and waste management practices. Upholding ethical and scientific principles across its operations and clinical research, the Company prioritized data protection and patient privacy. Anticipating future regulatory requirements, it proactively laid the groundwork for compliance with the Corporate Sustainability Reporting Directive and European Sustainability Reporting Standards. The reporting structure underwent refinement to incorporate financial materiality considerations.

Business ethics
Nykode Therapeutics, in collaboration with its partners, conducts preclinical experiments in animals as well as clinical trials. The experiments are approved by the Animal Welfare Committee in Nykode and obtains licenses from the Norwegian Food Safety Authority (Mattilsynet) to conduct trials on animals. Nykode only uses R&D vendors and laboratories that are approved and have documented high standards and expertise in animal research. The clinical trials are performed in accordance with the ethical and scientific principles governing clinical research on human subjects, as set out in the Declaration of Helsinki and the International Conference on Harmonization (ICH) guidelines on Good Clinical Practice. Nykode collaborates with international, competent service providers that specialize in these types of studies and consults with leading experts on trial design to optimize trial conduct. The Company has a continuous focus and monitoring of its internal routines and the Company's compliance with relevant legislation. Nykode is subject to the GDPR, incorporated in the Norwegian Personal Data Act (2018). The GDPR requires the Company to have e.g. records of processing activities, privacy statements, data protection policies, risk assessments and data processing agreements. The Company conducts regular assessments of its GDPR compliance level as well as GDPR awareness training. The Company has no reported personal data breaches, no pending cases with data protection authorities and no claims from third parties regarding GDPR non-compliance. Nykode is committed to maintaining the highest standards of ethical conduct and will not tolerate the use of bribery or corruption to achieve its business objectives. The Company has established anti-corruption policies according to which all employees must decline any expensive gifts, money, trips or other such offerings from business contacts. Nykode also meets the requirements of the Norwegian Transparency Act and the most recent Transparency Act statement can be found at Nykodes web-page (www.nykode.com).

ESG highlights

Number of employees

173

Number of clinical trials, ongoing and applied for

5

Diversity Staff

F:68%/M:32%

Diversity Board

F:38%/M:62%

Regulatory breaches

0

Waste tonnes

3.3

GHG (tonnes CO_2e market based)

5 491

(market-based, Scope 1, 2 and 3)

RISK AND UNCERTAINTY

Research and development

Engaging in the development of innovative pharmaceutical products inherently involves substantial risks, encompassing factors such as patent protection, clinical trials, and regulatory approvals within the realm of research and development. Nykode seeks to mitigate these risks through appropriate measures. The Company focuses on securing sufficient patent protection by collaborating closely with external patent advisors to minimize the risk of patent infringement claims as well as to prepare any patent defense should this be necessary. Nykode's regulatory department works closely with external regulatory consultants and regulatory agents to develop regulatory strategies and frequently interacts with regulatory agencies to navigate complex approval processes. Careful selection of clinical candidates is central to the company's risk management approach, with a diverse pipeline of candidates and clinical studies spanning various indications. The design of clinical trials strictly adheres to best practices and international regulations to minimize risk, with specialized Clinical Research Organizations (CROs) engaged to support these efforts. The clinical trials are carried out in collaboration with esteemed international partners with solid experience in conducting such trials and are conducted according to all applicable quality standards.

Commercial risk
The Group faces commercial risks associated with various aspects of its operations, including research and development, manufacturing, and commercialization of products, within a competitive landscape. These risks include:

- Competition from other companies developing alternative or similar therapies, which may impact the Company's ability to conduct clinical trials, seek regulatory approval, and achieve future sales.
- Partnerships and collaborations with key entities such as Genentech, Regeneron and MSD, which may be impacted by factors such as their ability to provide R&D support and willingness to develop and promote products, as well as overall market conditions.
- Adverse events affecting the Company's products, such as safety concerns or negative publicity, potentially leading to significant impacts on the Company’s results and cash flows.
- The expiration or loss of patent protection, along with challenges or invalidation of patents or patent applications, which could adversely affect the Company’s future results and cash flows.

Despite these risks, proactive measures are being taken to address them. This includes ongoing risk assessments, strategic planning, and close collaboration with partners to capitalize on their expertise and minimize potential negative impacts.

Market risk
The long-term financial success of the the Company requires obtaining marketing authorizations and securing acceptable reimbursement for its drugs. There can be no assurance that the Company's drugs will attain cost-effective selling prices or reimbursement rates. The Company's products are subject to approvals from regulatory authorities, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), to market its products in their respective regions, as well as equivalent regulatory authorities in other jurisdictions worldwide to commercialize products in those regions.

Successful launches and sales for pipeline products may not be achieved due to changes in market dynamics or competition, unsuccessful marketing, and/or pricing pressure due to limitations on healthcare budgets. Any such adverse events could have a material impact on the Company's financial results and cash flows.

As with any drug intended for diagnostic or therapeutic use, adverse clinical reactions are always a possibility. This could have a significant impact on the Company's reputation and financial position.



Financial risk
Nykode is exposed to financial risk factors, including risks associated with cash management, the short-term liquidity profile of development programs, liquidity from partnerships and the ability to attract capital from financial markets. The Company has not entered into any hedging agreements to reduce financial risk as of December 31, 2023.

The expected main sources of capital to secure future funding are the capital markets, the license and collaboration agreements with Genentech and Regeneron, potential new collaboration agreements with partners and potential funding from grant applications.

The Company is exposed to currency risk as employee expenses are primarily in Norwegian Kroner (NOK) and Danish Kroner (DKK), and much of its operating expenses for the clinical trials are paid in foreign currency, primarily in Euro (EUR). The Company keeps bank deposits in NOK, DKK, GBP, EUR and USD for operational purposes, and to reduce its currency risk. The Company regularly considers its current risk management of foreign exchange rates and will adjust it if deemed appropriate.

Nykode has purchased and maintains a Directors and Officers Liability Insurance on behalf of the members of the Board of Directors and the CEO. The insurance also covers any employee acting in a managerial capacity and includes controlled subsidiaries. The insurance policy is issued by reputable insurers with an appropriate rating.

IT-related risk
Nykode uses external assistance from qualified vendors to provide advice on cybersecurity and systems security where relevant. Its IT systems use authentication systems to reduce the risk of unauthorized access into its systems. The Company has appropriate protection from viruses and malware. Nykode has implemented procedures for IT security and data management via its IT vendors. Server back-ups are run automatically at regular intervals.

Going Concern

Pursuant to § 3.3 (a) of the Norwegian Accounting Act, it is confirmed that the conditions for assuming that the Group is a going concern are present, and that the financial statements have been prepared on the basis of this assumption. No events have occurred since the end of 2023, except those which are stated in this report that are of major significance for the assessment of the Company's financial position and results.

Events after balance sheet date

Non-adjusting events
There have been no other significant non-adjusting events after the reporting date, December 31, 2023.

RESPONSIBILITY STATEMENT

We confirm that, to the best of our knowledge, that the financial statements for the period from January 1 to December 31, 2023 have been prepared in accordance with IFRS adopted by EU and gives a true and fair view of the Group and the Company's consolidated assets, liabilities, financial position and results of operations, and that the Report of the Board of Directors provides a true and fair view of the development and performance of the business and the position of the Group and the Company together with a description of the key risks and uncertainty factors that the Company is facing.

Oslo, April 18, 2024

Board of Directors, Nykode Therapeutics ASA

Martin Nicklasson
Chair of the Board

Anders Tuv
Board Member

Bernd Robert Seizinger
Board Member

Harald Arnet
Board Member

Birgitte Volck
Board Member

Christian Åbyholm
Board Member

Anne Whitaker
Board Member

Elaine Sullivan
Board Member

Michael Thyrring Engsig
CEO

SENIOR MANAGEMENT

Michael Engsig

Chief Executive Officer
Michael Engsig joined Nykode in 2017. He is a broadly anchored pharmaceutical professional with extensive experience, from early-stage drug discovery to late-stage development and product launches in biotech and pharma and across all major geographical areas. His career history includes specialist and managerial roles at Takeda and Nycomed. He is a board member of Fluoguide A/S. Michael holds a civil engineering (MSc) degree in chemistry specializing in biotechnology from the Technical University of Denmark, and a Graduate Diploma in Business Administration (HD) in organization and leadership from the Copenhagen Business School (CBS).

Agnete B. Fredriksen

Chief Scientific Officer and Co-founder
Agnete Fredriksen is co-founder of Nykode and has served in various roles in Nykode management. Her previous employers include Affitech AS and Medinnova AS. She is the author of numerous scientific papers in the field of immunology, immunotherapy and vaccines, and has been awarded several patents in the field of immunotherapy. She is a board member of Molecular Partners AG. Agnete holds an MSc and a Ph.D. from the Institute of Immunology, Rikshospitalet Medical Center in Oslo, where she designed and developed the first Vaccibody™ vaccine molecules. She received the King's Gold Medal of Merit for her Ph.D. thesis describing vaccibodies.

Klaus Edvardsen

Chief Research & Development Officer
Klaus Edvardsen joined Nykode in 2022. He has extensive experience from leading drug development programs within oncology, hematology and infectious diseases in both biotech and pharma companies. His previous roles include Chief Development Officer of CureVac, and Senior Vice President and Head of Global Oncology Development of Merck KGaA, where he led early- and late-stage global oncology development. Prior to these roles, he served as Senior Vice President and Head of Global Medicines Development Oncology at AstraZeneca and various leadership roles at both GlaxoSmithKline and Genmab. Klaus holds a M.D. degree as well as a Ph.D. in cancer biology from University of Copenhagen.

Ulrich Blaschke

Chief Technology Officer
Ulrich Blaschke joined Nykode as Chief Technology Officer in January 2024. He has a strong background in leading integrated global biopharmaceutical development programs with international teams. Prior to joining Nykode, Ulrich held senior and leadership positions in different companies, including BioNTech, CureVac, and Boehringer Ingelheim. Ulrich studied Chemistry and Biochemistry at the University of Münster, Germany. After his PhD studies, he joined Rockefeller University, New York as a postdoctoral fellow, working in the field of synthetic protein chemistry.

Harald Gurvin

Chief Financial Officer
Harald Gurvin joined Nykode as Chief Financial Officer in 2021. He has a long career in the field of finance. Prior to joining Nykode, he served as Chief Financial Officer at Flex LNG, a company owning and operating LNG carriers and listed on both the New York and Oslo Stock Exchanges. He also served as Chief Financial Officer of SFL Corporation Limited, a leading international ship-owning company listed on the New York Stock Exchange. Harald holds an MSc in Shipping, Trade and Finance from Bayes Business School (formerly CASS) and a MSc in Marine Engineering and Naval Architecture from the Norwegian University of Science and Technology (NTNU).

Louise Stubbe

Chief Legal Officer
Louise Stubbe joined Nykode as Chief Legal Officer in 2022. She brings over a decade of life sciences industry experience from both private and public companies. Louise has a diverse career background in the biotech, MedTech and pharma industries. Most recently, she served as Vice President, Group General Counsel, at KemPharm and Orphazyme, where she built the global legal department. Prior to these roles, she served as Senior Corporate Legal Counsel at Ambu and LEO Pharma, where she held various roles in the law department. Louise holds a law degree (cand.jur.) from the University of Copenhagen in Denmark.

BOARD OF DIRECTORS

Martin Nicklasson

Chair of the Board of Directors,
Chair of Remuneration Committee,
Member of Audit Committee
Martin Nicklasson, Ph.D. has served as Chair of the Board of Directors since December 2021. From 2007 to end 2010, he served as President and Chief Executive Officer of Biovitrum AB and Swedish Orphan Biovitrum AB (Sobi). From 1999 to 2007, he held various Executive Vice President positions at AstraZeneca PLC and was a member of the Senior Executive Committee. Martin has held and holds various chair and board member positions in biotech and biopharma companies. Currently, he serves as chair of Zealand Pharma A/S and on the board of Basilea Pharmaceutica Ltd. Martin is a certified pharmacist and holds a Ph.D. in Pharmaceutical Technology from Uppsala University, Sweden.

Anders Tuv

Board Member, Chair of Audit Committee,
Member of Remuneration Committee
Anders Tuv has served on the Board of Directors since 2012. He serves as Managing Director of Radforsk Invest, a shareholder of Nykode, which is focused on immunotherapies and precision medicines. He is an experienced investment and business development professional with broad experience from the life science industry. His roles and responsibilities cover management positions, strategy and business development, research collaborations, licensing deals, M&A and IPOs. Anders holds several chair and non-executive director positions within biotech and MedTech companies. He holds a business degree (Siviløkonom) from the BI Norwegian Business School.

Harald Arnet

Board Member, Member of Remuneration Committee
Harald Arnet has served on the Board of Directors since May 2023. He serves as Chief Executive Officer, president and partner of the Datum Group, an investment company based in Oslo, Norway, a position he has held for over 25 years. Datum Group is the largest shareholder of Nykode. Prior to joining the Datum Group, he held management positions at former Samuel Montague & Co., HSBC and Handelsbanken, where he served as General Manager, Banking and led the Corporate Finance department in Norway. He holds several board positions in both listed and non-listed companies. Harald holds a BSBA from the University of Denver, USA, and has completed executive management courses at the London Business School.

Bernd R. Seizinger

Board Member, Member of R&D Committee
Bernd R. Seizinger, M.D., Ph.D. has served on the Board of Directors since 2014. His previous roles include CEO and Senior Executive positions at GPC Biotech, Genome Therapeutics Corporation and Bristol-Myers Squibb. Before entering the biotech and pharma industries, he was a Senior Faculty Member of Harvard Medical School/ Massachusetts General Hospital and Princeton University. Bernd serves as chair or board member of several public and private biotech companies in the U.S. and Europe, including Aprea, Aptose, BioInvent, CryptoMedix, Oncolytics and Oxford BioTherapeutics. In addition, he serves on the advisory board of Pureos BioVentures (Zurich) and is senior advisor to Hadean Ventures (Stockholm and Oslo). Bernd is a medical doctor and holds a Ph.D. in neurobiology.

Elaine Sullivan

Board Member, Chair of R&D Committee
Elaine Sullivan, Ph.D. has served on the Board of Directors since May 2022. She is a Senior pharmaceutical and biotech industry executive with over 25 years of international experience with a successful track record in science, investment, business development, and start-ups. She has extensive global leadership experience including membership of the top senior global R&D management teams at Eli Lilly (US) and AstraZeneca (UK). She was a member of the corporate steering and investment committees. She has developed new molecules in therapy areas including virology, cancer, ophthalmology, respiratory and inflammation. Other former positions include co-founder and CEO of Carrick Therapeutics, which developed a novel oncology pipeline rapidly transitioning from a preclinical start-up to a clinical stage oncology company. She sits on several international boards for companies in the biotech, services and adjacent areas. Elaine holds a Ph.D. in Molecular Virology from the University of Edinburgh and she was named Ernst Young Emerging Entrepreneur of the Year (Ireland).

Birgitte Volck

Board Member, Member of R&D Committee
Birgitte Volck, M.D., Ph.D. has served on the Board of Directors sin May 2021. She most recently served as Executive Vice President, Interim Chief Medical Officer and Head of Clinical Development and Medical Affairs of Ascendis Pharma A/S (Nasdaq: ASND). Previous senior positions in big pharma and biotech also include: President, Head of R&D, Avrobio Inc; Head of R&D in Rare Diseases for GlaxoSmithKline; and Chief Medical Officer and Senior Vice President of Development at Swedish Orphan Biovitrum AB (Sobi). Birgitte serves as a non-executive director of Soleno Therapeutics Inc. (Nasdaq: SLNO). Her career also includes previous non-executive director positions at Ascendis Pharma, Wilson Therapeutics, TFS International as well as various positions at Amgen Inc., including Executive Development Director of Bone, Neuroscience & Inflammation. Birgitte received her M.D. and Ph.D. degrees from the University of Copenhagen, Denmark.

Anne Whitaker

Board Member, Member of Remuneration Committee, Member of R&D Committee
Anne Whitaker has served on the Board of Directors since May 2022. She is an experienced executive with more than 30 years of experience in the life sciences industry, spanning large pharmaceutical, biotech, and specialty pharmaceutical companies. Her extensive leadership background includes CEO roles at three clinical-stage biotech businesses: Aerami Therapeutics, Synta Pharmaceuticals and Novoclem Therapeutics. This is complemented by significant experience in larger pharma, notably at Bausch Health, Sanofi and GSK. At GSK, she held senior commercial roles at both local U.S. and global levels and was responsible for running Sanofi's North American commercial and medical operations. She also serves as a non-executive director of several international companies. Anne holds a Bachelor of Science in Chemistry from the University of North Alabama, USA.

Christian Åbyholm

Board Member, Member of Audit Committee
Christian Åbyholm has served on the Board of Directors since January 2020. He is a partner at Andenæsgruppen, a shareholder of Nykode. His prior professional experience and past roles include M&A, business development and equity research with Norsk Hydro, Aker RGI, Morgan Stanley and Merrill Lynch. Christian is a CFA Charter holder, has an MBA from IMD, and holds a business degree (siviløkonom) from the Norwegian School of Economics and Business Administration. In addition, he completed the first two years of law school at the University of Oslo.

Einar J. Greve

Deputy Board Member
Einar J. Greve has served as Deputy Board Member since May 2022, prior to which he served as a Board Member from January 2020. He works as a strategic advisor with Cipriano AS. He was previously a partner of Wikborg Rein & Co and a partner of Arctic Securities ASA. He has held and holds various positions as chair and board member of both Norwegian and international listed and unlisted companies. Einar holds a Master of Law degree (cand.jur.) from the University of Oslo.

Trygve Lauvdal

Observer to the Board
Trygve Lauvdal, Ph.D. has served as Observer to the Board since December 2021, prior to which he served as a Board Member from April 2020. He is an Investment Director with RASMUSSENGRUPPEN AS, a shareholder of the Nykode. Prior to joining RASMUSSENGRUPPEN AS, he worked as an equity analyst with DNB Markets and as product manager with ABB. He has held several board positions with Norwegian companies. Trygve holds a Ph.D. in Engineering Cybernetics from the Norwegian University of Science and Technology (NTNU).

CORPORATE GOVERNANCE

CORPORATE GOVERNANCE

1. Implementation and reporting on corporate governance
Nykode will seek to comply with the Norwegian Code of Practice for Corporate Governance (the "Code"). The Board shall include a report on the Company's corporate governance in its annual report, including an explanation of any deviations from the Code.

Deviations from the Code: None

2. Business
Nykode's business is clearly defined in the Company's Articles of Association as follows: "to develop biomedical products and services". The business of the Company's and subsidiaries is conducted in compliance with the objective set forth in the Company's articles of association.

The Board defines clear objectives, strategies and risk profiles for the Company's business activities such that the Company creates value for shareholders in a sustainable manner. When carrying out this work, the Board takes into account financial, social and environmental considerations. The Board evaluates the objectives, strategies and risk profiles at least once a year.

Deviations from the Code: None

3. Equity and dividends
The Board will ensure that the Company has a capital structure that is appropriate to the Company's objective, strategy and risk profile, thereby ensuring that there is an appropriate balance between equity and other sources of financing. The Board will continuously assess the Company's capital requirements related to the Company's objective, strategy and risk profile.

The Company is committed to create long-term value for its shareholders. The Board may resolve to establish and disclose a clear and predictable dividend policy, or alternatively, if the Board considers the Company to be in a phase of growth, the Board may decide not to establish and disclose a dividend policy or to pay dividends. The background for any proposal to grant the Board an authorization to approve distribution of dividends will be explained.

General authorizations for the Board to increase the share capital and buy own shares will normally be restricted to defined purposes and will, in general, be limited in time to no later than the date of the next annual general meeting of the Company.

At the Company's annual general meeting on May 11, 2023, the Board was granted authorization to increase the share capital by a maximum amount of NOK 295,494, equal to 10% increase in outstanding shares at the time of the general meeting. The authorization is valid until the annual general meeting in 2024, however no longer than June 30, 2024. Existing shareholders' pre-emptive rights to subscribe for and to be allocated shares may be derogated from. The authorization may be used in connection with (i) capital raisings for the financing of the company's business; (ii) in connection with acquisitions and mergers, or (iii) to increase the spread of ownership in the shares. The company utilized this authorization in a private placement on October 25, 2023, whereby the share capital was increased by an amount of NOK 295,494. The private placement was conducted to finance the Company's business and increase the spread of ownership in the shares.

The Board was also granted authorization to increase the share capital by a maximum amount of NOK 50,000 in one or more share capital increases through issuance of new shares in connection with incentive programs. The Company did not utilize this authorization in 2023.

The Company has historically not distributed dividends and is not expected to do so in the near future.

Deviations from the Code: None

4. Equal treatment of shareholders
There is only one class of shares in the Company and all of the Company's shares carry equal rights.

All shareholders will be treated on an equal basis, unless there is a just cause for treating them differently in accordance with applicable laws and regulations. In the event of an increase in share capital of the Company through issuance of new shares, a decision to waive the existing shareholders' pre-emptive rights to subscribe for shares will be justified. If the Board resolves to issue new shares and waive the pre-emptive rights of existing shareholders pursuant to a Board authorization granted by the general meeting, the justification will be publicly disclosed in a stock exchange announcement issued in connection with the share issue. The reasons for any deviation from equal treatment of all shareholders in capital transactions will be included in the stock exchange announcement made in connection with the transaction.

The private placement completed on October 25, 2023 was carried out based on the authorization given to the Board at the annual general meeting on May 11, 2023. The private placement indicated a deviation from existing shareholder's pre-emptive right to subscribe for shares. The justification for deviating from the pre-emptive rights was publicly disclosed in the stock exchange announcement issued in connection with the private placement.

Any transactions carried out by the Company in the Company's own shares will be carried out through Oslo Stock Exchange and in any case at prevailing stock exchange prices. In the event that there is limited liquidity in the Company's shares, the Company will consider other ways to ensure equal treatment of shareholders. Any transactions in own shares will be evaluated in relation to the rules on the duty of disclosure, as well as in relation to the prohibition against illegal insider trading and market manipulation, the requirement for equal treatment of all shareholders, and the prohibition of unreasonable business methods.

Deviations from the Code: None

5. Shares and negotiability
The shares of the Company are freely negotiable. The Company will not limit any party's ability to own, trade or vote for shares in the Company. The Company will provide an account of any restrictions on owning, trading or voting for shares in the Company.

Deviations from the Code: None

6. General meetings
All shareholders have the right to participate in the general meetings of the Company, which exercise the highest authority of the Company. The annual general meeting will normally be held before June 30 each year.

The Board will ensure that:

I. the resolutions and supporting information distributed are sufficiently detailed, comprehensive and specific to allow shareholders to form a view on all matters to be considered at the meeting;
II. any deadline for shareholders to give notice of their intention to attend the meeting is set as close to the date of the meeting as possible;
III. members of the Board and the chair of the nomination committee have the possibility to attend the general meeting. The Company will, however, normally not have the entire Board attend the general meeting as this is considered unnecessary; and
IV. the general meeting will normally be chaired by the Chair of the Board or an individual appointed by the Chair of the Board. Having the Chair of the Board or a person appointed by him/her chairing the general meetings simplifies the preparations for the general meetings significantly. In the Company's experience, its procedures for the chairmanship and execution of general meetings have proven satisfactory.

Shareholders in the Company will be able to vote on each individual matter, including on each individual candidate nominated for election. Shareholders who cannot attend the meeting will be given the opportunity to vote. The Company will design the form for the appointment of a proxy to make voting on each individual matter possible and will nominate a person who can act as a proxy for shareholders

Deviations from the Code: None

7. Nomination committee
Nykode has established a nomination committee as laid down in the Company's articles of association. The general meeting has stipulated guidelines for the duties of the nomination committee. The guidelines were latest amended at the Company's annual general meeting on May 12, 2022.

The nomination committee shall consist of two or three members. The Company's general meeting elects the members of the nomination committee and determines their remuneration. Members are elected for two years at a time, unless otherwise resolved by the general meeting.

The nomination committee shall have contact with shareholders, the Board and the Company's executive personnel as part of its work on proposing candidates for election to the Board.

The members of the nomination committee shall be selected to take into account the interests of shareholders in general. The majority of the committee will be independent of the Company's Board and the executive personnel. The nomination committee shall not include any of the Company's executive personnel or any member of the Board.

The nomination committee's duties will be to propose candidates for election to the Board and nomination committee and to propose the fees to be paid to members of these bodies.

The nomination committee has guidelines to address the company's need for competence and diversity, as outlined in the corporate governance charter as well as the nomination committee charter. The purpose is to ensure a reasonable representation in terms of gender and background.

At the Company's annual general meeting held on May 11, 2023, Lars Lund-Roland was elected chair of the nomination committee. The two other members, Lars Erik Larsson and Jan Fikkan, were elected at the annual general meeting held on May 12, 2022, and were not up for re-election.

Deviations from the Code: None

8. Board of Directors, composition and independence
The Company's articles of association stipulate that the Board shall consist of two to eight members elected by the shareholders. The Chair of the Board is elected by the general meeting.

The composition of the Board shall ensure that the Board can attend to the common interests of all shareholders and meets the Company's need for expertise, capacity and diversity.

The composition of the Board shall ensure that it can operate independently of any special interests. The majority of the shareholder-elected members of the Board shall be independent of the Company's executive personnel and material business contacts. At least two of the members of the Board elected by shareholders shall be independent of the Company's main shareholder(s).

The Board shall not include members of the Company's executive personnel. If the Board does include executive personnel, the Company will provide an explanation for this and implement consequential adjustments to the organization of the work of the Board, including the use of board committees to help ensure more independent preparation of matters for discussion by the Board, cf. Section 9 of the Code.

The current Board, excluding Harald Arnet, was elected at the annual general meeting held on May 12, 2022. Harald Arnet was elected at the annual general meeting held on May 11, 2023. The biographies of the individual board members can be found in the annual report and on Nykode's website. The composition of the Board satisfies the independence requirements set forth in the Code.

An overview of the number of shares in the Company owned by board members as of December 31, 2023 is included in the notes to the financial statements (Note 6.1 Remuneration to Executive Management and the Board of Directors).

Deviations from the Code: None

9. The work of the Board of Directors
The Board has issued instructions for its own work as well as for the executive management with particular emphasis on clear internal allocation of responsibilities and duties.

The Board will present any agreements with related parties, either of the Board or the executive management, in their annual directors' report. The Board will also ensure that members of the Board and the Company's executive personnel make the Company aware of any material interests that they may have in items to be considered by the board of directors.

In order to ensure a more independent consideration of matters of a material character in which the Chair of the Board is, or has been, personally involved, the Board's consideration of such matters will be chaired by some other member of the Board.

The Board will provide details in the annual report of any board committees appointed.

The Board will evaluate its performance and expertise annually.

Committees
The Board has established three sub-committees in the form of the Audit Committee, Remuneration Committee and Research and Development Committee. The committees are preparatory and advisory working committees and assist the Board with the preparation of items for consideration. Decisions are made, however, by the full Board.

The Audit Committee is a preparatory and advisory select committee for the board of directors of the Company. The committee shall prepare the Board's supervision of the Company's financial reporting process and monitor the systems for internal control and risk management. The committee shall have continuous contact with the Company's auditor regarding the audit of the annual accounts and review and monitor the independence of the Company's auditor, including in particular the extent to which services other than auditing provided by the auditor or the audit firm represent a threat to the independence of the auditor.

The Remuneration Committee shall recommend the Company's remuneration policy for the executive management for final approval by the Board prior to approval by the general meeting. The committee will make proposals to the Board on remuneration of the executive management and to the Nomination Committee on remuneration for Board members. This is to ensure that the remuneration for the above-mentioned stakeholders is following the Company's remuneration guidelines. The committee will review the executive managements' annual business performance achievements against predefined annual corporate goals.

The Research and Development Committee shall oversee matters relating to the Company's scientific and technological capabilities and development programs and report to the Board regarding such matters to help facilitate Board oversight of (1) the Company's investment in research and development, product improvements and technology and (2) the Company's strategy and processes regarding engagement of the scientific community, support of research and clinical studies and development of scientific data generated by the Company's products. The committee will also monitor and evaluate significant emerging trends and issues in science and technology relevant to the Company and assist the Board and management in implementing appropriate advisory and thought-leader interactions.

Deviations from the Code: None

10. Risk management and internal control
As a listed company, the Company is committed to maintaining a sound system of risk management and internal control that is appropriate for the size, complexity, and risk profile of our business. The Board will carry out an annual review of the Company's most important areas of exposure to risk and internal control arrangements.

The Company has established clear procedures for identifying, assessing, and managing risks, and regularly evaluates and updates these practices to ensure their effectiveness. Significant risks, including strategic, financial, liquidity, and operational risks, are assessed on an ongoing basis and at least once a year by the Board.

The finance function is responsible for the preparation of the Company's financial statements and reports, ensuring compliance with IFRS and other applicable laws and regulations. The annual financial statements are reviewed by the Company's auditor, and the main features of our internal control and risk management systems as they relate to financial reporting are provided in the annual report.

The Company has also established mechanisms to prevent and address corruption, fraud, bribery, and other irregularities, including internal channels for reporting that protect the identity of the reporter if required.

Deviations from the Code: None

11. Remuneration of the Board of Directors
The annual general meeting determines the Board's remuneration annually on the basis of the recommendations of the Nomination Committee. The remuneration of the Board shall reflect the Board's responsibility, expertise, time commitment and the complexity of the Company's activities. Work in sub-committees may be compensated in addition to the remuneration received for Board membership. Members of the Board, and/or companies with which they are associated with, shall not take on specific assignments for the Company in addition to their appointment as a member of the Board. If they do nonetheless take on such assignments, this shall be disclosed to the full Board. The remuneration for such additional duties shall be approved by the Board.

In line with the internationalization of the Company and its board composition over the last years, the Company has chosen to deviate from the recommendation that the Board should not receive share options. The remuneration of the Board approved at the general meeting in 2023 consists both of cash and share options, as is common in the international market.

Deviations from the Code: The Company has granted share options to members of the Board

12. Salary and other remuneration for executive personnel

The guidelines for remuneration of executive management are prepared by the Board for consideration of the annual general meeting. The current guidelines were approved at the annual general meeting held on May 11, 2023 and are available on the Company's website. The main principles of the remuneration policy are; i) remuneration shall be market competitive, but not leading; ii) remuneration shall be motivational and drive value creation for shareholders; iii) remuneration shall be transparent and acceptable both internally and externally; and iv) remuneration shall be flexible, allowing adjustments over time. The remuneration scheme is based on the following; i) base salary; ii) short term incentive plan; iii) long term incentive plan; iv) pension benefits; v) other terms of employment.

More detailed information about the remuneration of executive management may be found in the report on remuneration to executive management, which is available on the Company's website.

Deviations from the Code: None

13. Information and communications

The Board has established guidelines for the Company's reporting of financial and other information and for contact with shareholders other than through general meetings. The Company ensures that relevant, accurate and timely information is made available to the market as a basis for fair pricing and regular ttrading of the Company's shares, and that the Company is perceived as a visible, accessible, reliable and professional company by the capital market, while at the same time always observing the rules and legislation for listed companies on the Oslo Stock Exchange. The guidelines include policy on who is entitled to speak on behalf of the company on various subjects.

Deviations from the Code: None



14. Take-overs
The Board has prepared guidelines for how to act in the event of a possible takeover bid for the Company. The purpose of the guidelines is to safeguard the interests of the shareholders in respect to a possible rumored or actual offer for the outstanding shares in the Company. The Board shall not seek to hinder or obstruct any takeover bid unless there are justifiable grounds for doing so based on the Company's and the shareholder's collective interests. The Board will ensure that all shareholders are treated equally in a takeover process and shall not institute measures with the intention of protecting the personal interests of its members at the expense of the interests of the shareholders. The Board will generally seek to ensure that the values and interests of the shareholders are protected and that shareholder value is maximized. The Board will evaluate any bid and issue a statement on the Board's opinion of the bid, and if required obtain a valuation from an independent expert.

Deviations from the Code: None

15. Auditors
The Company's external auditor is Deloitte AS. On an annual basis, the Board reviews with the auditor the Company's internal control procedures, including identified risk areas and proposals for improvement, as well as the main features of the plan for the audit of the Company. The auditor must annually present to the Board a plan of the audit work and a written confirmation that the auditor satisfies established requirements as to independence and objectivity.

Furthermore, the auditor participates in meetings of the Board that deal with the annual accounts and, at least once a year, carries out a review of the Company's procedures for internal control in collaboration with the audit committee. At least one Board meeting with the auditor shall be held each year in which no member of the senior management is present.

The Board of Directors has established guidelines in respect of the use of the auditor by the senior management for services other than the audit, to ensure that the auditor's independence and objectivity as an auditor is not compromised.

The remuneration to the auditor will be approved by the ordinary general meeting. The Board of Directors will report to the general meeting details of fees for audit work and any fees for other specific assignments.

Deviations from the Code: None




FINANCIAL
STATEMENTS

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

Group			For the years ended December 31		Parent	
2023	**2022**	**Notes**	**Amounts in USD '000**	**Notes**	**2023**	**2022**
12,902	7,168	2.2	Revenue from contracts with customers	2.2	12,902	7,168
421	1,861		Other income		460	1,861
13,323	**9,029**		**Total revenue and other income**		**13,362**	**9,029**
27,482	18,047	2.3	Employee benefit expenses	2.3	18,331	11,771
41,801	42,325	2.4	Other operating expenses	2.4	49,564	47,740
2,122	1,813	3.1, 3.2	Depreciation	3.1, 3.2	1,947	1,666
(58,082)	**(53,156)**		**Operating profit or loss**		**(56,480)**	**(52,148)**
18,674	8,637	4.6	Finance income	4.6	18,686	8,646
4,678	6,464	4.6	Finance costs	4.6	4,635	6,498
(44,086)	**(50,983)**		**Profit or loss before tax**		**(42,429)**	**(50,000)**
(8,932)	(8,240)	5.1	Income tax expense	5.1	(9,037)	(8,320)
(35,154)	**(42,743)**		**Profit or loss for the year**		**(33,392)**	**(41,680)**
			Other comprehensive income:			
			Items that subsequently may be reclassified to profit or loss:			
(4)	78		Foreign currency translation effects		—	—
(4)	78		Total items that may be reclassified to profit or loss		—	—
(4)	**78**		**Total other comprehensive income for the year**		—	—
(35,158)	**(42,665)**		**Total comprehensive income for the year**		**(33,392)**	**(41,680)**
			Earnings per share ("EPS"):			
(0.12)	(0.15)	4.8	Basic EPS - profit or loss attributable to equity holders	4.8	(0.11)	(0.14)
(0.12)	(0.15)	4.8	Diluted EPS - profit or loss attributable to equity holders	4.8	(0.11)	(0.14)

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

Group				Parent	
31.12.2023	31.12.2022	Notes	Amounts in USD '000	31.12.2023	31.12.2022
			ASSETS		
			Non-current assets		
4,413	3,517	3.1	Property, plant and equipment	4,309	3,517
6,104	6,009	3.2	Right-of-use assets	5,290	5,998
70	32		Intangible assets	70	32
31,923	46	2.9	Other non-current receivables	31,923	6
42,510	**9,604**		**Total non-current assets**	**41,592**	**9,553**
—	—	4.9	Investments in subsidiaries	4,318	2,199
—	—		Loans to subsidiaries	—	884
—	**—**		**Total financial non-current assets**	**4,318**	**3,083**
			Current assets		
—	2,544	2.5	Trade receivables	—	2,544
3,073	2,943	2.5	Other receivables	2,901	2,830
162,602	206,386	4.5	Cash and cash equivalents	161,542	205,696
165,675	**211,873**		**Total current assets**	164,443	211,070
208,185	**221,477**		**TOTAL ASSETS**	**210,353**	**223,706**
			EQUITY AND LIABILITIES		
			Equity		
367	338	4.4	Share capital	367	338
128,986	83,318		Share premium	128,986	83,318
15,395	11,694		Other capital reserves	15,393	11,692
(3,048)	(3,044)		Other components of equity	(3,113)	(3,113)
29,559	64,713		Retained earnings	33,199	66,591
171,259	**157,018**		**Total equity**	**174,832**	**158,826**
			Non-current liabilities		
4,269	4,365	3.2	Non-current lease liabilities	3,624	4,365
2	30	2.7	Non-current provisions	2	30
12,047	21,079	5.1	Deferred tax liabilities	12,040	21,079
16,318	**25,474**		**Total non-current liabilities**	**15,666**	**25,474**
			Current liabilities		
104	133		Government grants	104	133
1,457	1,147	3.2	Current lease liabilities	1,242	1,136
7,064	10,175	2.6	Trade and other payables	6,911	10,897
3,750	7,714	2.7	Current provisions	3,365	7,504
8,233	19,736	2.8	Current contract liabilities	8,233	19,736
—	80	5.1	Income tax payable	—	—
20,608	**38,985**		**Total current liabilities**	**19,855**	**39,406**
36,926	**64,459**		**Total liabilities**	**35,521**	**64,881**
208,185	**221,477**		**TOTAL EQUITY AND LIABILITIES**	**210,353**	**223,706**

Oslo, April 18, 2024

Board of Directors, Nykode Therapeutics ASA

Martin Nicklasson
Chair of the Board

Anders Tuv
Board Member

Bernd Robert Seizinger
Board Member

Harald Arnet
Board Member

Birgitte Volck
Board Member

Christian Åbyholm
Board Member

Anne Whitaker
Board Member

Elaine Sullivan
Board Member

Michael Thyrring Engsig
CEO

CONSOLIDATED STATEMENT OF CASH FLOWS

Group			For the years ended December 31		Parent	
2023	2022	Notes	Cash flows from operating activities (USD '000)	Notes	2023	2022
(44,086)	**(50,983)**		**Profit or loss before tax**		(42,429)	(50,000)
			Adjustments to reconcile profit before tax to net cash flows:			
(180)	—		Income tax expense		—	—
(13,299)	(1,264)	4.6	Net financial income/expense	4.6	(13,307)	(1,419)
629	415	3.1	Depreciation of property, plant and equipment	3.1	616	407
1,493	1,399	3.2	Depreciation of Right-of-use assets	3.2	1,330	1,259
3,701	3,832	4.7	Share-based payment expense	4.7	1,582	2,584
			Working capital adjustments:			
2,414	21,972	2.5	Changes in trade receivables and other receivables	2.5	2,890	22,963
(29,000)	455	2.9	changes in other non-current receivables	2.9	(29,038)	483
(2,772)	2,281	2.6	Changes in trade and other payables	2.6	(4,406)	3,517
(15,496)	6,085	2.7, 2.8	Changes in contract liabilities, current provisions and government grants	2.7,2.8	(15,333)	5,878
—	—		Changes in contract liabilities		—	—
(28)	(4,885)	2.7	Changes in non-current provisions	2.7	(28)	(4,879)
(96,624)	**(20,693)**		**Net cash flows from/(used in) operating activities**		**(98,123)**	**(19,207)**
			Cash flows from investing activities (USD '000)			
(1,902)	(2,675)	3.1	Purchase of property, plant and equipment*	3.1	(1,785)	(2,675)
—	10,042	4.1	Proceeds from sale of Money Market Funds	4.1	—	10,042
8,942	3,683	4.6	Interest received	4.6	8,938	3,673
—	—		Payment of loan to subsidiaries		—	(884)
—	—		Receipt from loan to subsidiaries		884	–
7,040	**11,050**		**Net cash flows from investing activities**		**8,037**	**10,156**
			Cash flows from financing activities (USD '000)			
45,697	1,797	4.4	Proceeds from issuance of equity	4.4	45,697	1,797
(893)	(1,197)	3.2	Payments for the principal portion of the lease liability	3.2	(801)	(984)
(215)	(207)	3.2	Payments for the interest portion of the lease liability	3.2	(175)	(207)
—	(33)	4.6	Interest paid	4.6	—	(21)
44,589	**360**		**Net cash flows from financing activities**		**44,721**	**585**
(44,995)	(9,285)		**Net increase/(decrease) in cash and cash equivalents**		(45,365)	(8,466)
206,386	216,231	4.5	Cash and cash equivalents at beginning of the year/period	4.5	205,696	214,722
1,211	(560)		Net foreign exchange difference		1,211	(560)
162,602	**206,386**		**Cash and cash equivalents, end of year**		**161,542**	**205,696**

* Purchase of PPE is adjusted for non-cash items due to timing of payment.

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

Group

Amounts in USD '000	Share capital	Share premium	Other capital reserves	Other components of equity	Retained earnings	Total equity
Balance at January 1, 2022	**333**	**81,526**	**7,863**	**(3,122)**	**107,455**	**194,055**
Profit or (loss) for the year	—	—	—	—	(42,743)	(42,743)
Other comprehensive income	—	—	—	78	—	78
Issue of share capital (Note 4.4)	5	1,792	—	—	—	1,797
Share-based payments (Note 4.7)	—	—	3,831	—	—	3,831
Balance at December 31, 2022	**338**	**83,318**	**11,694**	**(3,044)**	**64,713**	**157,018**
Profit or (loss) for the year	—	—	—	—	(35,154)	(35,154)
Other comprehensive income	—	—	—	(4)	—	(4)
Issue of share capital (Note 4.4)	29	45,668	—	—	—	45,697
Share-based payments (Note 4.7)	—	—	3,701	—	—	3,701
Balance at December 31, 2023	**367**	**128,986**	**15,395**	**(3,048)**	**29,559**	**171,259**

Parent

Amounts in USD '000	Share capital	Share premium	Other capital reserves	Other components of equity	Retained earnings	Total equity
Balance at January 1, 2022	**333**	**81,526**	**7,849**	**(3,113)**	**108,271**	**194,866**
Profit or (loss) for the year	—	—	—	—	(41,680)	(41,680)
Issue of share capital (Note 4.5)	5	1,792	—	—	—	1,797
Share-based payments (Note 4.8)	—	—	3,843	—	—	3,843
Balance at December 31, 2022	**338**	**83,318**	**11,692**	**(3,113)**	**66,591**	**158,826**
Profit or (loss) for the year	—	—	—	—	(33,392)	(33,392)
Issue of share capital (Note 4.4)	29	45,668	—	—	—	45,697
Share-based payments (Note 4.7)	—	—	3,701	—	—	3,701
Balance at December 31, 2023	**367**	**128,986**	**15,393**	**(3,113)**	**33,199**	**174,832**

1.1 General information

Corporate information
The financial statements of Nykode Therapeutics ASA and its subsidiaries ("Nykode" or "the Group") for the year ended December 31, 2023 were authorized for issue in accordance with a Board resolution on April 18, 2024. Nykode Therapeutics ASA ("Parent Company" or "Parent") has shares traded on the Oslo Stock Exchange, with the ticker symbol NYKD. Nykode Therapeutics ASA is incorporated and domiciled in Norway, and the address of its registered office is Gaustadalléen 21, 0349 Oslo, Norway.

The Group consists of clinical-stage biopharmaceutical companies, dedicated to the discovery and development of novel immunotherapies for the treatment of cancer and autoimmune diseases. Nykode's modular vaccine technology specifically targets antigens to Antigen Presenting Cells, which have been shown to induce broad, strong and long-lasting antigen specific immune response in cancer, which correlates with clinical responses. Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the treatment of human papilloma virus 16 induced malignancies which demonstrated positive efficacy and safety results from its Phase 2 trial for the treatment of cervical cancer. VB10.16 is being expanded into multiple trials for treatment of head and neck cancer and cervical cancer. VB10.NEO, an individualized cancer neoantigen vaccine, is exclusively out licensed to Genentech Inc. ("Genentech"), a member of the Roche Group. The Group has collaborations with Genentech within oncology and a multi-target collaboration with Regeneron Pharmaceuticals Inc. ("Regeneron") within oncology and infectious diseases.

1.2 Basis of preparation

The financial statements of the Group and Parent Company comprise statement of comprehensive income, statement of financial position, statement of cash flows, statement of changes in equity, and related notes. The financial statements have been prepared in accordance with International Financial Reporting Standards as adopted by the European Union ("IFRS®").

The financial statements have been prepared on a historical cost basis, except for financial instruments measured at fair value. The financial statements are prepared based on the going concern assumption.

Comparative financial information is provided for the preceding period in the statement of comprehensive income, statement of financial position, statement of equity and statement of cash flows.

The consolidated financial statements comprise the financial statements of the Parent Company and its subsidiaries as at December 31, 2023. Control is achieved when the Group is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee.

Inter-company transactions, balances and unrealized gains on transactions between group companies are eliminated. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of the transferred asset. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the group.

Presentation currency and functional currency
The financial statements are presented in US dollars ("USD"), which is the functional currency of the Parent Company. All USD amounts are rounded to the nearest thousand, unless otherwise noted. The financial statements of consolidated foreign subsidiaries whose functional currency is not USD are translated into USD for statement of financial position items at the closing exchange rate at the date of the statement of financial position and for the statement of total comprehensive income at the average rate for the period presented.

1.3 Material accounting policies

Nykode's material accounting policies are described in each of the individual notes to the consolidated financial statements. Accounting policies listed below are regarded as the principal accounting policies applied by Management:

- Revenue from contracts with customers (note 2.2)
- Right-of-use assets and lease liabilities (note 3.2)
- Taxes (note 5.1)

1.4 Material accounting judgements, estimates and assumptions

The preparation of the financial statements in accordance with IFRS and applying the chosen accounting policies requires management to make judgements, estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances. Actual results may differ from these estimates. The estimates and the underlying assumptions are reviewed on an ongoing basis.

The accounting policies applied by management which includes a significant degree of estimates and assumptions or judgements that may have the most significant effect on the amounts recognized in the financial statements, are summarized below:

Accounting judgements:
- Determining the performance obligations under the Regeneron Agreement (note 2.2)
- Determining whether deferred tax assets should be recognized (note 5.1)

A detailed description of the significant accounting judgements is included in the individual note where applicable.

Estimates and assumptions:
- Identification of performance obligations (note 2.2)
- Measurement of deferred tax liability (note 5.1)

Nykode based its assumptions and estimates on parameters available when the financial statements were prepared. Existing circumstances and assumptions about future developments, however, may change due to market changes or circumstances arising that are beyond the control of the Group. Such changes are reflected in the assumptions when they occur.

A detailed description of the significant estimates and assumptions are included in the individual note where applicable.

2.1 Operating segment

Operating segments are reported in a manner consistent with the internal reporting provided to the Chief Operating Decision Maker ("CODM") for segment performance and resource allocation. This is reported as one segment as the nature of the activities are similar across the Group. Nykode has identified the Board of Directors as the CODM

In the table below non-current assets are broken down by geographical areas based on the location of the operations:

Group			Parent	
31.12.2023	**31.12.2022**	**Non-current assets**	**31.12.2023**	**31.12.2022**
41,593	9,553	Norway	41,593	9,553
917	51	Denmark	–	–
42,510	**9,604**	**Total non-current assets**	**41,593**	**9,553**

Non-current assets for this purpose consist of property, plant and equipment, intangible assets, right-of-use assets and other non-current receivables.

Revenue from contracts with customers that amounted to more than 10% of the Groups revenue in 2023 and 2022 is as follows:

Group			Parent	
2023	**2022**	**Revenue from contracts with customers**	**2023**	**2022**
12,045	6,308	Revenue from Customer 1	12,045	6,308
857	860	Revenue from Customer 2	857	860
12,902	**7,168**	**Total revenue from contracts with customers**	**12,902**	**7,168**

2.2 Revenue from contracts with customers

ACCOUNTING POLICIES

Revenue from sale of licenses

Revenue from sale of licenses relates to the sale of intellectual property ("IP"). For licenses of intellectual property that are distinct (or represent the predominant item of a combined performance obligation), the Group assesses whether the license provides the customer with a right to access the Nykode IP as it exists throughout the license period ("a right to access") or a right to use the Nykode IP as it exists at the point in time in which the license is granted ("a right to use"). Revenue from licenses that provide the customer with "a right to access" is accounted for over time as the performance occurs. Revenue from licenses with "a right to use" is recognized at the time when the license is granted to the customer and when the customer is able to use and benefit from the license.

Revenue from R&D services

Revenue from conduction of R&D services relates to Nykode's delivery of R&D activities. Revenue is recognized over time or point in time based on the type of R&D activities. R&D activities that are delivered based on specific instructions and Nykode has an unconditional right to consideration once performed. Nykode also delivers R&D activities on specific projects where it conducts research and provides the customer with the clinical outcome. Such services are recognized as performance obligations satisfied over time. Revenue is recognized based on the stage of completion of the contract, this is based on the actual incurred cost relative to the total expected cost for these services.

Variable consideration

If the consideration in a contract includes a variable amount, Nykode estimates the amount of consideration to which it will be entitled in exchange for transferring the goods and services to the customer. The variable consideration is estimated at contract inception and constrained until it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the associated uncertainty with the variable consideration is subsequently resolved.

Amounts of variable consideration of sale-based royalties promised in the exchange for a license of intellectual property are not included in the transaction price or recognized as revenue until the subsequent sale occurs.

Transaction price

Nykode allocates the total transaction price in proportion to the stand-alone selling price of each promised good or service in a contract. If a stand-alone selling price is not directly observable, Nykode estimates the stand-alone selling price that best depicts the amount of consideration to which the Group expects to be entitled in exchange for transferring the goods or services to the customer.

Group			Parent	
2023	**2022**	**Revenue from contracts with customers**	**2023**	**2022**
12,902	7,168	R&D services	12,902	7,168
12,902	**7,168**	**Total revenue**	**12,902**	**7,168**

Group			Parent	
2023	**2022**	**Geographical distribution**	**2023**	**2022**
12,902	7,168	United States of America	12,902	7,168
12,902	**7,168**	**Total revenue**	**12,902**	**7,168**

The revenue information above is based on the locations of the customers.

Group			Parent	
2023	**2022**	**Timing of revenue recognition**	**2023**	**2022**
857	860	Goods/services transferred at a point in time	857	860
12,045	6,308	Services transferred over time	12,045	6,308
12,902	**7,168**	**Total revenue**	**12,902**	**7,168**

The transaction price allocated to the remaining performance obligations (unsatisfied or partially unsatisfied) as at December 31 are as follows:

Group			Parent	
2023	**2022**		**2023**	**2022**
5,904	15,486	Within one year	5,904	15,486
2,556	6,019	More than one year	2,556	6,019
8,460	**21,505**	**Total**	**8,460**	**21,505**

The remaining performance obligations expected to be recognized within one year and in more than one year relates to the R&D services under the Genentech Agreement.

MATERIAL ACCOUNTING JUDGEMENTS AND ESTIMATES
Significant accounting judgements and estimates related to the Regeneron Agreement and the Genentech Agreement are listed below.

Determining the performance obligations
Regeneron Agreement
Based on an overall assessment of the agreement and the nature of the deliverables it has been determined that the license of intellectual property, the R&D activities and the manufacturing services do not significantly modify each other and are three distinct performance obligations. It has further been assessed that Nykode is not providing a significant service of integrating these deliverables into one combined output. Also, the use of the license is not highly dependent on, or highly interrelated with, the R&D activities or the manufacturing services. In making these assessments, emphasis has been put on the standardized nature of the R&D services and the manufacturing services and the fact that a third-party Clinical Research Organization or Contract Manufacturing Organization could have provided these services to Regeneron under their supervision.

Estimates of variable consideration
The assessment of amounts included in the transaction price upon inception of the contract is subject to judgement as there may be significant uncertainty related to the total consideration to be paid under the agreement

Contract balances
Contract assets and contract liabilities relate to revenue earned from ongoing services. As such, the balances of these accounts vary and depend on the number of ongoing projects at the end of the year. The Group presents its trade receivables arising from contracts with customers separately from contract assets and contract liabilities. Accounting policies and balances for trade receivables are presented in note 2.5 and contract assets and contract liabilities are presented in note 2.8.

2.3 Employee benefit expenses

Group			Parent	
2023	**2022**	**Employee benefit expenses**	**2023**	**2022**
18,847	15,644	Salaries	12,898	11,312
2,699	3,862	Social security costs	2,699	3,851
2,057	1,574	Pension costs	1,057	925
3,700	3,843	Share-based payment expense	1,581	2,584
(826)	(8,002)	Social security cost on share-based payments	(826)	(8,002)
1,005	1,126	Other employee expenses	922	1,101
27,482	**18,047**	**Total employee benefit expenses**	**18,331**	**11,771**
159	132	**Average number of full-time employees (FTEs)**	129	109

Pensions

The Group has a defined contribution pension plan for its employees which satisfies the statutory requirements under the Norwegian law on required occupational pension ("lov om obligatorisk tjenestepensjon"). For the Group's employees in Denmark, the Group has established a pension scheme which satisfies the requirements under Danish law.

The schemes are defined contribution plans. Contributions are paid to pension insurance plans and charged to the income statement in the period to which the contributions relate. Once the contributions have been paid, there are no further payment obligations.

Due to the decrease in Nykode's share price and the exercise of warrants during the year ended 2023 and 2022, there is a corresponding decrease in the accrual for social security tax related to share-based payments. For the year December 31, 2023 this resulted in a decrease of employee benefit expenses of USD 0.8 million, compared to an decrease of USD 8.0 million for the year ended December 31, 2022.

At the end of the reporting period, members of the Board of Directors and Executive Management held shares and warrants/options in Nykode Therapeutics ASA. For information on remuneration to Executive Management and the Board of Directors, see note 6.1.

2.4 Other operating expenses

Group			Parent	
2023	**2022**	**Other operating expenses**	**2023**	**2022**
29,358	26,774	Research and development expenses	29,355	26,676
3,142	4,744	Consulting fees	3,107	4,634
1,723	2,492	Legal expenses	1,633	2,171
2,723	2,359	Operating materials	2,723	2,359
1,413	1,656	Audit and accounting fees	1,278	1,511
933	753	Lease expenses	707	678
503	472	Duty and handling costs	500	472
1,014	751	Travel expenses	709	483
–	–	Purchase of services from subsidiaries	8,796	6,576
992	2,324	Other operating expenses	756	2,180
41,801	**42,325**	**Total other operating expenses**	**49,564**	**47,740**

Total research and development expenses for 2023 were USD 51.2 million (USD 47.9 million for 2022), of which USD 29.4 million (USD 26.8 million) was recognized as other operating expense, with the remainder recognized as employee benefit expenses in the statement of comprehensive income.

Group			Parent	
2023	**2022**	**Auditor fees**	**2023**	**2022**
1,100	1,240	Audit fee	1,088	1,223
6	32	Assurance services	6	32
20	57	Tax services	20	57
–	5	Other services	–	5
1,126	**1,334**	**Total remuneration to the auditor**	**1,114**	**1,317**

Audit fee:
The amounts above are excluding VAT.

2.5 Trade and other receivables

Group			Parent	
31.12.2023	31.12.2022	**Trade receivables**	31.12.2023	31.12.2022
–	2,544	Trade receivables from customers at nominal value	–	2,544
–	**2,544**	**Total trade receivables**	**–**	**2,544**

31.12.2023	31.12.2022	**Other receivables**	31.12.2023	31.12.2022
750	525	VAT receivable	680	442
115	848	Government grants receivables	115	848
2,007	1,154	Prepaid expenses	1,906	1,093
201	416	Other receivables	200	405
–	–	Receivables from group companies	–	42
3,073	**2,943**	**Total other receivables**	**2,901**	**2,830**

The credit risk of financial assets has not increased significantly from initial recognition. For details regarding the Group's procedures on managing credit risk, reference is made to note 4.3.

No credit losses allowance are recognized at year end 2023 or 2022.

	Trade receivables				
		Past due but not impaired			
Ageing analysis of trade receivables	**Not due days**	**< 30 days**	**31-60 days**	**> 60 days**	**Total**
Trade receivables at December 31, 2023	–	–	–	–	–
Trade receivables at December 31, 2022	2,544	–	–	–	2,544

2.6 Trade and other payables

Group			Parent	
31.12.2023	31.12.2022	Trade and other payables	31.12.2023	31.12.2022
1,327	2,313	Trade payables	1,203	2,485
1,529	2,765	Withholding payroll taxes and social security	1,303	2,764
1,215	689	Accruals for payroll, bonus and board remuneration	606	364
2,993	4,408	Other accrued expenses	2,960	4,059
–	–	Payables to group companies	839	1,225
7,064	**10,175**	**Total trade and other payables**	**6,911**	**10,897**

For trade and other payables aging analysis, see note 4.2.

2.7 Provisions

The Group classifies provisions in the following categories:

- Salary related costs: Contains a provision for accrued holiday pay.
- Social security for share-based payments: Contains a provision for the accrued social security on share options and restrictive share units which will be paid when the options are exercised/fully vested.
- Onerous contract: Contains the recognition of an onerous contract for R&D services to a customer.

A provision is made and calculated based on management assumptions at the time the provision is made and is updated as and when new information becomes available. All provisions are reviewed at the end of the financial year.

Other commitments and contingencies

Contingent liabilities are not recognized in the annual accounts. Significant contingent liabilities are disclosed, with the exception of contingent liabilities where the possibility of an outflow of economic resources is considered remote.

Contingent assets are not recognized in the annual accounts but are disclosed when an inflow of economic benefits is considered probable.

The Group has no contingent assets or liabilities that meet the criteria for disclosure.

Other commitments

The Group did not provide guarantees to or on behalf of third parties or related parties. The Group has no other significant commitments to disclose.

Onerous contracts

Present obligations arising under onerous contracts are recognized and measured as provisions. An onerous contract is considered to exist where the Group has a contract under which the unavoidable costs of meeting the obligations under the contract exceed the economic benefits expected to be received under it.

Reconciliation of provisions:

Group

Amounts in USD '000	Salary related costs	Social security for share based payments	Onerous contract	Total
At January 1, 2022	**812**	**9,338**	**—**	**10,150**
Additional provisions made	1,648	—	8,280	**9,928**
Amounts used	(695)	(1,894)	(3,051)	**(5,639)**
Unused amounts reversed	(112)	(6,583)	—	**(6,695)**
At December 31, 2022	**1,653**	**861**	**5,230**	**7,744**
Current provisions	*1,653*	*831*	*5,230*	*7,714*
Non-current provisions	*—*	*30*	*—*	*30*
At January 1, 2023	**1,653**	**861**	**5,230**	**7,744**
Additional provisions made	1,874	2	—	**1,876**
Amounts used	(1,147)	(588)	(3,354)	**-5,089**
Unused amounts reversed	(506)	(273)	—	**(779)**
At December 31, 2023	**1,874**	**2**	**1,876**	**3,752**
Current provisions	*1,874*	*—*	*1,876*	*3,750*
Non-current provisions	*—*	*2*	*—*	*2*

Parent

Amounts in USD '000	Salary related costs	Social security for share based payments	Onerous contract	Total
At January 1, 2022	**809**	**9,338**	**—**	**10,147**
Additional provisions made	1,444	—	8,280	**9,724**
Amounts used	(697)	(1,894)	(3,051)	**(5,642)**
Unused amounts reversed	(112)	(6,583)	—	**(6,695)**
At December 31, 2022	**1,444**	**861**	**5,230**	**7,534**
Current provisions	*1,444*	*831*	*5,230*	*7,504*
Non-current provisions	*—*	*30*	*—*	*30*
At January 1, 2023	**1,444**	**861**	**5,230**	**7,534**
Additional provisions made	1,489	2	—	**1,491**
Amounts used	(1,144)	(588)	(3,354)	**(5,086)**
Unused amounts reversed	(300)	(273)	—	**(573)**
At December 31, 2023	**1,489**	**2**	**1,875**	**3,366**
Current provisions	*1,489*	*—*	*1,875*	*3,364*
Non-current provisions	*—*	*2*	*—*	*2*

2.8 Contract liabilities

ACCOUNTING POLICIES
Contract liabilities
A contract liability is recognized if a payment is received or a payment is due (whichever is earlier) from a customer before the Group transfers the related goods or services. Contract liabilities are recognized as revenue when the Group performs under the contract (i.e., transfers control of the related goods or services to the customer). Contract asset or contract liability positions are presented on a net basis for each contract.

Group			Parent	
2023	**2022**	**Contract assets/liabilities (-)**	**2023**	**2022**
(19,736)	**(16,044)**	**At January 1**	**(19,736)**	**(16,044)**
—	(10,000)	Additions	—	(10,000)
(542)	—	Reclassified to trade receivables	(542)	—
12,045	6,308	Rendering of service in the period	12,045	6,308
(8,233)	**(19,736)**	**Total contract assets/liabilities (-) at December 31**	**(8,233)**	**(19,736)**

Contract liabilities are recognized when fulfilling performance obligations, mainly from the recognition of the service component under the Genentech Agreement where progress is measured over time (See note 2.2). When the consideration becomes unconditional, the contract assets will be reclassified to trade receivables. The main part of the changes to contract assets/liabilities in the period are related to milestone payments received, and reclassification to trade receivables.

The Group expects to realize USD 5.9 million of the contract liability in 2024. The contract liability is classified as a current liability as it will be realized in the entity's normal operating cycle.

2.9 Other non-current receivables

Group			Parent	
31.12.2023	31.12.2022	Other non-current receivables	31.12.2023	31.12.2022
8	46	Deposits	8	6
31,915	–	Tax receivable	31,915	–
31,923	**46**	**Total other non-current receivables**	**31,923**	**6**

A significant component of the other non-current receivable per December 31, 2023 is the payment to the Norwegian Tax Authorities (NTA) following their negative decision, where the NTA reiterated their position that the up-front payments received under a license agreement entered into in 2020 should be treated as taxable income in full in 2020, rather than the use of taxable gain/loss account whereby part of the taxable income would be deffered to subsequent years.

Nykode has appealed the decision to the Norwegian Tax Administration (Norw: Skatteklagenemda).

3.1 Property, plant and equipment

Group					Parent			
Machinery and plant	Fixtures, office machinery etc.	Lab facility	Total		Machinery and plant	Fixtures, office machinery etc.	Lab facility	Total
1,113	**348**	**580**	**2,041**	**Cost as at January 1, 2022**	**1,113**	**348**	**580**	**2,041**
1,863	333	19	2,215	Additions	1,863	333	19	2,215
-107	107	—	—	Reclassifications	-107	107	—	—
-158	-57	—	-215	Disposals and write-offs	-158	-57	—	-215
2,711	**731**	**599**	**4,041**	**Cost as at December 31, 2022**	**2,711**	**731**	**599**	**4,041**
1,374	151	—	1,525	Additions	1,374	35	—	1,409
4,085	**882**	**599**	**5,566**	**Cost as at December 31, 2023**	**4,085**	**766**	**599**	**5,450**
90	**67**	**—**	**157**	**Depreciation as at January 1, 2022**	**90**	**67**	**—**	**157**
118	135	114	367	Depreciation	118	135	114	367
208	**202**	**114**	**524**	**Depreciation as at December 31, 2022**	**208**	**202**	**114**	**524**
354	175	100	629	Depreciation	354	163	100	617
562	**377**	**214**	**1,153**	**Depreciation as at December 31, 2023**	**562**	**365**	**214**	**1,141**
				Net book value:				
1023	**281**	**580**	**1884**	**At January 1, 2022**	**1,023**	**281**	**580**	**1,884**
2503	**529**	**485**	**3517**	**At December 31, 2022**	**2,503**	**529**	**485**	**3,517**
3523	**505**	**385**	**4413**	**At December 31, 2023**	**3,523**	**401**	**385**	**4,309**
6-10	**3-5**	**6**		**Economic life (years)**	**6-10**	**3-5**	**6**	
Straight-line method				**Depreciation plan**	**Straight-line method**			

No indicators for impairment of property, plant and equipment were identified in the current or prior period.

At December 31, 2023, fixed assets are located across the entire Group.

3.2 Right-of-use assets and lease liabilities

ACCOUNTING POLICIES

At inception of a contract, the Group assesses whether the contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, the Group assesses whether:

- The agreement creates enforceable rights of payment and obligations
- The identified asset is physically distinct
- The supplier does not have a substantive right to substitute the asset throughout the period of use
- It has the right to obtain substantially all of the economic benefits from use of the asset
- It has the decision-making rights that are most relevant to changing how and for what purpose the asset is used throughout the contract period

The Group as a lessee

At the commencement date, the Group recognizes a lease liability and corresponding right-of-use asset for all lease agreements in which it is the lessee, except for the following exemptions applied:

- Short-term leases (defined as 12 months or less)
- Low value assets

For these leases, the Group recognizes the lease payments as operating expenses in the statement of comprehensive income.

Measuring the lease liability

The lease liability is initially measured at the present value of the lease payments for the right to use the underlying asset during the lease term that are not paid at the commencement date. The lease term represents the non-cancellable period of the lease, together with periods covered by an option to extend the lease when the Group is reasonably certain to exercise this option, and periods covered by an option to terminate the lease if the Group is reasonably certain not to exercise that option.

The lease payments included in the measurement comprise:

- Fixed lease payments, less any lease incentives received.
- Variable lease payments that depend on an index or a rate, initially measured using the index or rate as at the commencement date.

The lease liability is subsequently measured by increasing the carrying amount to reflect interest on the lease liability, reducing the carrying amount to reflect the lease payments made and remeasuring the carrying amount to reflect any reassessment or lease modifications, or to reflect adjustments in lease payments due to an adjustment in an index or rate.

The Group presents its lease liabilities as separate line items in the statement of financial position. Cash flows related to payments for the principal portion of the lease liability are classified within financing activities.

3.2 Right-of-use assets and lease liabilities (Continued)

The Group's leased assets

Nykode leases several assets, mainly office facilities and laboratories at Forskningsparken in Oslo, Norway. Nykode also leases office space in Denmark and office equipment. Leases of office space generally have lease terms up to six years. The Group also leases parking lots and office equipment that are expensed as incurred as they are either considered short term or of low value.

The Group's right-of-use assets recognized in the statement of financial position are presented in the table below:

Group			Right-of-use assets	Parent		
Fixtures, Office machinery etc.	Office buildings	Total		Fixtures, Office machinery etc.	Office buildings	Total
6	**8,342**	**8,348**	**Acquisition cost at January 1, 2022**	**6**	**8,217**	**8,223**
22	132	154	Additions of right-of-use assets	22	69	91
—	(5)	(5)	Adjustment of right-of-use assets	—	—	—
28	**8,469**	**8,497**	**Acquisition cost at December 31, 2022**	**28**	**8,286**	**8,314**
—	993	993	Additions of right-of-use assets	—	27	27
—	595	595	Adjustment of right-of-use assets	—	595	595
28	**10,057**	**10,085**	**Acquisition cost at December 31, 2023**	**28**	**8,908**	**8,936**
6	**1,061**	**1,067**	**Depreciation and impairment at January 1, 2022**	**6**	**1,037**	**1,043**
7	1,392	1,399	Depreciation of right-of-use assets	7	1,244	1,251
13	**2,453**	**2,466**	**Depreciation and impairment at December 31, 2022**	**13**	**2,281**	**2,294**
7	1,486	1,493	Depreciation of right-of-use assets	7	1,323	1,330
20	**3,939**	**3,959**	**Depreciation and impairment at December 31, 2023**	**20**	**3,604**	**3,624**
—	**22**	**22**	**Terminations of right-of use assets at December 31, 2022**	**—**	**22**	**22**
—	**—**	**—**	Terminations of right-of use assets	**—**	**—**	**—**
—	**22**	**22**	**Terminations of right-of use assets at December 31, 2023**	**—**	**22**	**22**
15	**5,994**	**6,009**	**Carrying amount at December 31, 2022**	**15**	**5,983**	**5,998**
8	**6,096**	**6,104**	**Carrying amount at December 31, 2023**	**8**	**5,282**	**5,290**
1	1-6		Remaining lease term or remaining useful life	1	1-6	
Straight-line method			Depreciation plan	Straight-line method		

2023	2022	Expenses in the period related to practical expedients and variable payments	2023	2022
70	37	Short-term lease expenses	—	12
16	3	Low-value assets lease expenses	15	3
—	—	Variable lease expenses in the period (not included in the lease liabilities)	—	—
86	**40**	**Total lease expenses in the period**	**15**	**15**

The lease expenses in the period related to short-term leases, low-value assets and variable lease payments are included in other operating expenses in the statement of comprehensive income, and the payments are presented in the Group's operating activities in the statement of cash flows.

3.2 Right-of-use assets and lease liabilities (Continued)

Group			Parent	
2023	2022	Changes in the lease liabilities	2023	2022
5,511	**7,170**	**At January 1**	**5,501**	**7,070**
1,028	154	New leases recognized during the period	27	92
(1,108)	(1,197)	Cash payments for the principal portion of the lease liability	(976)	(984)
(215)	(207)	Cash payments for the interest portion of the lease liability	(175)	(207)
215	207	Interest expense on lease liabilities	175	207
561	(5)	Adjustment of lease liabilities	595	—
—	(15)	Terminations	—	(15)
(266)	(596)	Currency translation effects	(281)	(663)
5,726	**5,511**	**Total lease liabilities at December 31**	**4,866**	**5,500**
1,457	1,147	Current lease liabilities in the statement of financial position	1,242	1,136
4,269	4,365	Non-current lease liabilities in the statement of financial position	3,624	4,365

Lease commitments not included in the lease liabilities

Inflation adjustments
In addition to the lease liabilities presented above, the Group is committed to pay variable lease payments for its office space, mainly related to future inflation adjustments which is estimated in the initial calculation of lease liabilities. The lease liability and right-of-use asset will be adjusted when the inflation adjustment has a cash flow effect.

Extension and termination options
The Group has some lease contracts that include extension and termination options. These options are negotiated by management to provide flexibility in managing the Groups business needs. Management applies judgement in evaluating whether it is reasonably certain whether or not to exercise the option to renew or terminate the lease. That is, they consider all relevant factors that create an economic incentive for it to exercise either the renewal or termination. After the commencement date, the Group reassesses the lease term if there is a significant event or change in circumstances that is within its control and affects its ability to exercise or not to exercise the option to renew or to terminate.

Other matters
The Group's leases do not contain provisions or restrictions that impacts the Group's dividend policies or financing possibilities. Further, the Group does not have significant residual value guarantees related to its leases.

4.1 Financial instruments

ACCOUNTING POLICIES
A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

Classification of financial instruments
The Group's financial instruments are grouped in the following categories:

Financial Assets
- Financial assets measured subsequently at amortized cost: Includes mainly trade and other receivables, contract assets, contract cost assets and cash and cash equivalents
- Financial assets measured subsequently at fair value through profit or loss: Includes other current financial assets (money market funds) and includes currency derivatives when the fair value is positive.

With the exception of other current financial assets, the Group's financial assets are part of the Group's business model with the sole objective to collect contractual cash flows. Additionally, the contractual terms of the financial assets give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding, thereby passing the "SPPI test", constituting debt instruments measured at amortized cost.

Financial Liabilities
- Financial liabilities measured subsequently at amortized cost: Represent the Group's non-interest bearing liabilities such as trade payables, contract liabilities and government grants.
- Financial liabilities measured at fair value through profit or loss: Includes currency derivatives when the fair value is negative.

Initial recognition and subsequent measurement
Financial assets and liabilities at amortized cost
The Group's financial assets and liabilities are initially recognized at fair value plus directly attributable transaction expenses. Subsequently, these instruments are measured at amortized cost using the effective interest method (EIR). Gains and losses are recognized in profit or loss upon impairment, when the instruments are derecognized as well as through the EIR amortization process.

Amortized cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the EIR. The amortization is included as finance costs in the statement of comprehensive income.

Financial assets and liabilities at fair value through profit or loss
Financial assets and liabilities at fair value through profit or loss are recognized at fair value are carried in the statement of financial position at fair value with net changes in fair value recognized in the statement of profit or loss.

The Group did not hold any derivative financial instruments at December 31, 2023 or December 31, 2022. The Group does no to apply hedge accounting.

Impairment of financial assets
Financial assets measured at amortized cost are considered for impairment by recognising an allowance for expected credit losses (ECLs). The Group applies a simplified approach in calculating ECLs, where the Group does not track changes in credit risk, but instead recognizes a loss allowance based on lifetime ECLs at each reporting date. The Group bases its ECLs on its historical losses, adjusted for forward-looking factors specific to the debtors and the economic environment. See note 4.3 for further information related to management of credit risk.

The Group considers a financial asset in default when contractual payments are more than 90 days past due. However, in certain cases, the Group may also consider a financial asset to be in default when internal or external information indicates that the Group is unlikely to receive the outstanding contractual amounts in full before taking into account any credit enhancements. A financial asset is written off when there is no reasonable expectation of recovering the contractual cash flows.

4.1 Financial instruments (Continued)

ACCOUNTING POLICIES (Continued)

Derecognition of financial instruments

A financial asset is derecognized when the rights to receive cash flows from the asset have expired, the Group has transferred its rights to receive cash flows from the asset or the Group has assumed an obligation to pay the received cash flows in full under a "pass-through" arrangement.

A financial liability is derecognized when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognized in the statement of comprehensive income.

Offsetting of financial instruments

Financial assets and financial liabilities are offset, and the net amount is reported in the statement of financial position if there is a currently enforceable legal right to offset the recognized amounts and there is an intention to settle on a net basis, to realise the assets and settle the liabilities simultaneously.

The Group's financial instruments are presented in the tables below:

Group

As at December 31, 2023	Notes	Financial instruments at amortized cost	Financial instruments at fair value through profit or loss	Total
Assets				
Other non-current receivables	2.9	31,923	–	**31,923**
Trade receivables	2.5	–	–	**–**
Other receivables	2.5	3,073	–	**3,073**
Other current financial assets				
Cash and cash equivalents	4.5	162,602	–	**162,602**
Total financial assets		**197,598**	**–**	**197,598**
Liabilities				
Trade and other payables	2.6	(7,064)	—	**(7,064)**
Non-current lease liabilities	3.2	(4,269)	—	**(4,269)**
Current lease liabilities	3.2	(1,457)	—	**(1,457)**
Total financial liabilities		**(12,790)**	**—**	**(12,790)**

4.1 Financial instruments (Continued)

Parent

As at December 31, 2023	Notes	Financial instruments at amortized cost	Financial instruments at fair value through profit or loss	Total
Assets				
Other non-current receivables	2.9	31,923	–	**31,923**
Trade receivables	2.5	–	–	**–**
Other receivables	2.5	2,901	–	**2,901**
Other current financial assets				
Cash and cash equivalents	4.5	161,542	–	**161,542**
Total financial assets		**196,366**	**–**	**196,366**
Liabilities				
Trade and other payables	2.6	(6,911)	—	**(6,911)**
Non-current lease liabilities	3.2	(3,624)	—	**(3,624)**
Current lease liabilities	3.2	(1,242)	—	**(1,242)**
Total financial liabilities		**(11,777)**	**—**	**(11,777)**

Group

As at December 31, 2022	Notes	Financial instruments at amortized cost	Financial instruments at fair value through profit or loss	Total
Assets				
Other non-current receivables	2.9	46	–	**46**
Trade receivables	2.5	2,544	–	**2,544**
Other receivables	2.5	2,943	–	**2,943**
Other current financial assets				
Cash and cash equivalents	4.5	206,386	–	**206,386**
Total financial assets		**211,919**	**–**	**211,919**
Liabilities				
Trade and other payables	2.6	(10,175)	—	**(10,175)**
Non-current lease liabilities	3.2	(4,365)	—	**(4,365)**
Current lease liabilities	3.2	(1,147)	—	**(1,147)**
Total financial liabilities		**(15,688)**	**—**	**(15,688)**

4.1 Financial instruments (Continued)

Parent

As at December 31, 2022	Notes	Financial instruments at amortized cost	Financial instruments at fair value through profit or loss	Total
Assets				
Other non-current receivables	2.9	6	–	**6**
Trade receivables	2.5	2,544	–	**2,544**
Other receivables	2.5	2,830	–	**2,830**
Other current financial assets				
Cash and cash equivalents	4.5	205,696	–	**205,696**
Total financial assets		**211,076**	**–**	**211,076**
Liabilities				
Trade and other payables	2.6	(10,897)	–	**(10,897)**
Non-current lease liabilities	3.2	(4,365)	–	**(4,365)**
Current lease liabilities	3.2	(1,136)	–	**(1,136)**
Total financial liabilities		**(16,398)**	**–**	**(16,398)**

There are no changes in classification and measurement for the Group's financial assets and liabilities.
Finance income and finance costs arising from the Group's financial instruments are disclosed separately in note 4.6.

4.2 Ageing of financial liabilities

Contractual undiscounted cash flows from financial liabilities are presented below:

Group

As at December 31, 2023	1-12 months	1-2 years	2-3 years	3-4 years	4-5 years	More than 5 years	Total
Financial liabilities							
Trade and other payables	7,064	—	—	—	—	—	**7,064**
Non-current lease liabilities	—	1,480	1,518	1,567	58	—	**4,623**
Current lease liabilities	1,468	—	—	—	—	—	**1,468**
Total financial liabilities	**8,532**	**1,480**	**1,518**	**1,567**	**58**	**—**	**13,155**

Parent

As at December 31, 2023	1-12 months	1-2 years	2-3 years	3-4 years	4-5 years	More than 5 years	Total
Financial liabilities							
Trade and other payables	6,911	—	—	—	—	—	**6,911**
Non-current lease liabilities	—	1,259	1,293	1,337	—	—	**3,889**
Current lease liabilities	1,251	—	—	—	—	—	**1,251**
Total financial liabilities	**8,162**	**1,259**	**1,293**	**1,337**	**—**	**—**	**12,051**

Group

As at December 31, 2022	1-12 months	1-2 years	2-3 years	3-4 years	4-5 years	More than 5 years	Total
Financial liabilities							
Trade and other payables	10,175	—	—	—	—	—	**10,175**
Non-current lease liabilities	—	1,121	1,122	1,152	1,182	—	**4,577**
Current lease liabilities	1,113	—	—	—	—	—	**1,113**
Total financial liabilities	**11,288**	**1,121**	**1,122**	**1,152**	**1,182**	**—**	**15,865**

Parent

As at December 31, 2022	1-12 months	1-2 years	2-3 years	3-4 years	4-5 years	More than 5 years	Total
Financial liabilities							
Trade and other payables	10,898	—	—	—	—	—	**10,898**
Non-current lease liabilities	—	1,121	1,122	1,152	1,182	—	**4,577**
Current lease liabilities	1,102	—	—	—	—	—	**1,102**
Total financial liabilities	**12,000**	**1,121**	**1,122**	**1,152**	**1,182**	**—**	**16,577**

4.2 Ageing of financial liabilities (Continued)

Reconciliation of changes in liabilities incurred as a result of financing activities:

Group			Non-cash changes			
2023	January 1	Cash flow effect	New leases	Foreign exchange movement	Other changes	December 31
Non-current lease liabilities	4,365	—	764	(196)	(664)	**4,269**
Current lease liabilities	1,147	(1,108)	263	(70)	1,225	**1,457**
Total liabilities from financing	**5,512**	**(1,108)**	**1,027**	**(266)**	**561**	**5,726**

Parent			Non-cash changes			
2023	January 1	Cash flow effect	New leases	Foreign exchange movement	Other changes	December 31
Non-current lease liabilities	4,365	—	13	(2089	(546)	**3,624**
Current lease liabilities	1,136	(976)	14	(73)	1,141	**1,242**
Total liabilities from financing	**5,501**	**(976)**	**27**	**(281)**	**595**	**4,866**

Group			Non-cash changes			
2022	January 1	Cash flow effect	New leases	Foreign exchange movement	Other changes	December 31
Non-current lease liabilities	5,820	—	27	(523)	(959)	**4,365**
Current lease liabilities	1,350	(1,119)	127	(151)	940	**1,147**
Total liabilities from financing	**7,170**	**(1,119)**	**154**	**(674)**	**(19)**	**5,512**

Parent			Non-cash changes			
2022	January 1	Cash flow effect	New leases	Foreign exchange movement	Other changes	December 31
Non-current lease liabilities	5,820	—	28	(523)	(960)	**4,365**
Current lease liabilities	1,250	(961)	64	(139)	922	**1,136**
Total liabilities from financing	**7,070**	**(961)**	**92**	**(662)**	**(38)**	**5,501**

4.3 Financial risk management

Overview
The Group's principal financial liabilities, comprise lease liabilities, and trade and other payables. The main purpose of these financial liabilities is to finance the Group's operations. The Group's principal financial assets include trade and other receivables, and cash and short-term deposits that derive directly from its operations.

The Group is exposed to a range of risks affecting its financial performance, including market risk, credit risk and liquidity risk. The Group seeks to minimise potential adverse effects of such risks through sound business practice, risk management and hedging.

Market risk
Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk for the Group comprises two types of risk: interest rate risk and currency risk. Financial instruments affected by market risk include cash and cash and cash equivalents, lease liabilities and trade and other payables.

Interest rate risk
Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Group has a limited exposure to the risk of changes in market interest rates for its financial liabilities as it has no interest bearing debt.

Interest rate sensitivity
The sensitivity to a possible change in interest rates, with all other variables held constant, on the Group's profit before tax, is illustrated below. In calculating the sensitivity analyses, the Group assumes that the sensitivity of the relevant statement of profit or loss item is the effect of the assumed changes in respective financial risks.

Interest rate sensitivity	Increase / decrease in basis points	Effect on loss before tax	Effect on equity
December 31, 2023	+/- 50	813	813
December 31, 2022	+/- 50	1,032	1,032

Foreign currency risk
Foreign currency risk is the risk that the fair value or future cash flows of an exposure will fluctuate because of changes in foreign exchange rates. The Group's exposure to the risk of changes in foreign exchange rates relates primarily to the Group's operating activities (income and expenses denominated in a foreign currency). The Group's income is denominated in USD while operating expenses are mainly denominated in USD, EUR, NOK and DKK. The Group's assets and liabilities at the end of the reporting period are mainly denominated in USD with some exposure to NOK (cash and cash equivalents and other receivables) as well as EUR and DKK (cash and cash equivalents).

The Group does not hedge currency exposure with the use of financial instruments at the current time, but monitors the net exposure over time.

Foreign currency sensitivity
The following table illustrates the sensitivity for a hypothetical increase or decrease in the foreign exchange rates in the period, holding all other variables constant:

Foreign currency sensitivity	Date	Change in FX rate	Effect on loss before tax	Effect on equity
Increase / decrease in NOK/USD	31.12.2023	+/- 10%	8,200	5,221
Increase / decrease in EUR/USD	31.12.2023	+/- 10%	2,128	2,128
Increase / decrease in DKK/USD	31.12.2023	+/- 10%	1,534	2,451
Increase / decrease in NOK/USD	31.12.2022	+/- 10%	2,814	3,016
Increase / decrease in EUR/USD	31.12.2022	+/- 10%	1,169	1,170
Increase / decrease in DKK/USD	31.12.2022	+/- 10%	254	923

Credit risk
Credit risk is the risk that a counterparty will not meet its obligations under a financial instrument or contract, leading to a financial loss.

The Group is exposed to credit risk related to trade and other receivables, other long-term receivables, contract assets and cash and cash equivalents. However, the credit risk is assessed to be low as the counterparty to these assets are mainly Genentech, Regeneron, Nordea and DNB Bank ASA whose credit risks are low.

Liquidity risk
Liquidity risk is the risk that the Group will encounter difficulty in meeting obligations associated with financial liabilities that are settled by delivering cash or another financial asset. The Group monitors its risk to a shortage of funds by monitoring its working capital and securing sufficient funding.

The Group's objective is to secure funding for its working capital, including mainly the research and development of vaccines. The Group has a significant balance of cash and cash equivalents and the liquidity risk is assessed as low. An overview of the maturity profile of the Group's financial liabilities with corresponding cash flow effect is presented in note 4.2.

4.4 Equity and shareholders

Capital management
The Group's goal is to secure its shareholders a best possible long-term return on capital employed, measured as the aggregate of dividends and appreciation of the share value.

Nykode manages its capital structure and makes adjustments in light of changes in economic conditions. To maintain or adjust the capital structure, the Group may adjust the dividend payment, if any, to shareholders, return capital to shareholders, issue new shares or issue debt. Nykode monitors its capital using an equity ratio, which is 'total equity' divided by 'total assets'.

	31.12.2023	31.12.2022
Equity	171,259	157,018
Total assets	208,185	221,477
Equity ratio	**82%**	**71%**

ACCOUNTING POLICIES
Costs related to equity transactions
Transaction costs are deducted from equity, net of associated income tax.

Distribution to shareholders
Nykode recognizes a liability to make distributions to equity holders when the distribution is authorized and the distribution is no longer at the discretion of Nykode. As per the corporate laws of Norway, a distribution is authorized when it is approved by the shareholders. A corresponding amount is recognized directly in equity.

No distributions were made to shareholders in the current or prior period.

Issued capital and reserves:

Share capital in Nykode Therapeutics ASA	Number of shares authorized and fully paid	Par value per share (NOK)	Share Capital (USD '000)
At January 1, 2022	**289,619,409**	**0.01**	**333**
Share capital increase			
February 24, 2022	300,000	0.01	—
April 8, 2022	150,000	0.01	—
December 20, 2022	3,834,900	0.01	4
December 22, 2022	790,000	0.01	1
At December 31, 2022	**294,694,309**	**0.01**	**338**
Share capital increase			
February 1, 2023	800,000	0.01	1
October 31, 2023	29,549,400	0.01	27
November 10, 2023	531,802	0.01	—
November 28, 2023	796,933	0.01	1
December 7, 2023	174,000	0.01	—
At December 31, 2023	**326,546,444**	**0.01**	**367**

4.4 Equity and shareholders (Continued)

The share capital increase at October 31, 2023 relates to a private placement. All other share capital increases in the periods are related the exercise of warrants, see additional information in note 4.7.

At October 31, 2023 the Company issued 29,549,400 common shares at NOK 17.10 per share for a gross proceed of USD 45,003,230. In connection with this private placement the Company paid a fee of USD 1,745,389.

All shares are ordinary and have the same voting rights and rights to dividends.

Reconciliation of the Group's equity is presented in the statement of changes in equity.

Nykode Therapeutics' shareholders:

At December 31, 2023	Total shares	Ownership/ Voting rights
RASMUSSENGRUPPEN AS	30,180,750	9.2%
Datum Opportunity AS	26,000,000	8.0%
Radforsk Investeringsstiftelse	24,057,000	7.4%
Victoria India Fund AS	17,705,175	5.4%
State Street Bank And Trust Comp	12,735,824	3.9%
Datum AS	12,560,250	3.8%
Joh Johannson Eiendom AS	10,561,631	3.2%
Norda ASA	7,996,755	2.4%
Vatne Equity AS	7,485,857	2.3%
Om Holding AS	6,519,525	2.0%
Hortulan AS	5,184,808	1.6%
Portia AS	4,500,000	1.4%
Krag Invest AS	4,470,100	1.4%
Alden AS	4,202,500	1.3%
J.P. Morgan SE	3,471,645	1.1%
Skips AS Tudor	3,365,000	1.0%
Danske Invest Norge Vekst	3,137,203	1.0%
Borgano AS	3,000,000	0.9%
Skøien AS	2,850,000	0.9%
Danske Invest Norske Instit. Ii.	2,713,200	0.8%
Other shareholders	133,849,221	41.0%
Total	**326,546,444**	**100.0%**

At December 31, 2022	Total shares	Ownership/ Voting rights
RASMUSSENGRUPPEN AS	30,180,750	10.2%
Datum Opportunity AS	26,000,000	8.8%
Radforsk Investeringsstiftelse	24,057,000	8.2%
Victoria India Fund AS	17,255,175	5.9%
Datum AS	12,060,250	4.1%
Norda ASA	7,996,755	2.7%
Vatne Equity AS	7,375,000	2.5%
Joh Johannson Eiendom AS	6,937,641	2.4%
Om Holding AS	6,519,525	2.2%
Skøien AS	5,487,514	1.9%
Hortulan AS	5,187,508	1.8%
Portia AS	4,500,000	1.5%
Krag Invest AS	4,470,100	1.5%
Alden AS	3,607,500	1.2%
Skips AS Tudor	3,075,000	1.0%
Borgano AS	3,000,000	1.0%
Lani invest AS	2,674,225	0.9%
Datum Finans AS	2,395,500	0.8%
The Northern Trust Comp, London Br	2,335,274	0.8%
Sarsia Seed AS	2,100,000	0.7%
Other shareholders	117,479,592	39.9%
Total	**294,694,309**	**100.0%**

Shares held by the Board of Directors at the end of the reporting periods are summarized in note 6.1.

4.5 Cash and cash equivalents

Group			Parent	
31.12.2023	**31.12.2022**	**Cash and cash equivalents**	**31.12.2023**	**31.12.2022**
161,954	205,844	Bank deposits, unrestricted	160,894	205,153
648	543	Bank deposits, restricted*	648	543
162,602	**206,386**	**Total cash and cash equivalents**	**161,542**	**205,696**

*Bank deposits restricted for employee tax witholdings

4.6 Financial income and costs

ACCOUNTING POLICIES
Interest income and interest expenses are calculated using the effective interest method.

Foreign currency gains or losses are reported as gain or loss on foreign exchange within in finance income or finance costs, except for translation effects from functional currency to presentation currency which are presented within OCI. For other accounting policies related to the underlying financial instruments, reference is made to note 4.1.

Interest expense on lease liabilities represents the interest rate implicit in the lease, or the incremental borrowing rate used to measure the lease liabilities recognized in the statement of financial position, for further disclosures see note 3.2.

Group			Parent	
2023	**2022**	**Finance income**	**2023**	**2022**
9,728	4,809	Gain on foreign exchange	9,743	4,788
8,946	3,687	Interest income	8,943	3,716
—	142	Fair value gain on other current financial assets	—	142
18,674	**8,637**	**Total finance income**	**18,686**	**8,646**

Group			Parent	
2023	**2022**	**Finance costs**	**2023**	**2022**
4,454	6,046	Loss on foreign exchange	4,454	6,092
8	34	Interest expenses	7	22
216	207	Interest expense on lease liabilities	174	207
—	40	Realized loss on sales of money market fund	—	40
—	137	Other finance costs	—	137
4,678	**6,464**	**Total finance costs**	**4,635**	**6,498**

4.7 Share based payments

ACCOUNTING POLICIES
Employees (including members of the Board of Directors and management) of the Group receive remuneration in the form of share-based payments, whereby employees render services as consideration for equity instruments (equity-settled transactions).

Equity-settled transactions
The cost of equity-settled transactions is determined by the fair value at the date when the grant is made using an appropriate valuation model (the Black-Scholes-Merton Model).

That cost is recognized in employee benefits expense, together with a corresponding increase in equity (other capital reserves), over the period in which the service and, where applicable, the performance conditions are fulfilled (the vesting period). The cumulative expense recognized for equity-settled transactions at each reporting date until the vesting date reflects the extent to which the vesting period has expired and the Group's best estimate of the number of equity instruments that will ultimately vest. The expense or credit in the statement of profit or loss for a period represents the movement in cumulative expense recognized as at the beginning and end of that period.

Service and non-market performance conditions are not taken into account when determining the grant date fair value of awards, but the likelihood of the conditions being met is assessed as part of the Group's best estimate of the number of equity instruments that will ultimately vest. Market performance conditions are reflected within the grant date fair value. Any other conditions attached to an award, but without an associated service requirement, are considered to be non-vesting conditions. Non-vesting conditions are reflected in the fair value of an award and lead to an immediate expensing of an award unless there are also service and/or performance conditions.

No expense is recognized for awards that do not ultimately vest because non-market performance and/or service conditions have not been met. Where awards include a market or non-vesting condition, the transactions are treated as vested irrespective of whether the market or non-vesting condition is satisfied, provided that all other performance and/or service conditions are satisfied.

When the terms of an equity-settled award are modified, the minimum expense recognized is the grant date fair value of the unmodified award, provided the original vesting terms of the award are met. An additional expense, measured as at the date of modification, is recognized for any modification that increases the total fair value of the share-based payment transaction, or is otherwise beneficial to the employee. Where an award is cancelled by the entity or by the counterparty, any remaining element of the fair value of the award is expensed immediately through profit or loss.

The dilutive effect of outstanding options is reflected as additional share dilution in the computation of diluted earnings per share (further details are given in note 4.9).

Cash-settled transactions
A liability is recognized for the fair value of cash-settled transactions. The fair value is measured initially and at each reporting date up to and including the settlement date, with changes in fair value recognized in employee benefits expense The fair value is expensed over the period until the vesting date with recognition of a corresponding liability. The fair value is determined using an appropriate valuation model (the Black-Scholes-Merton Model). The approach used to account for vesting conditions when measuring equity-settled transactions also applies to cash-settled transactions.

Transactions where the Group has a choice of settlement in equity or in cash
Where the Group has choice of settlement, the accounting treatment is binary – in other words the whole transaction is treated either as cash-settled or as equity-settled, depending on whether or not the entity has a present obligation to settle in cash.

IFRS 2 requires a transaction to be treated as a liability (and accounted for using the rules for cash-settled transactions) if:

- the choice of settlement has no commercial substance (for example, because the entity is legally prohibited from issuing shares);
- the entity has a past practice or stated policy of settling in cash; or
- the entity generally settles in cash whenever the counterparty asks for cash settlement.

4.7 Share based payments (Continued)

Warrant and share option plan - Description

Nykode Therapeutics ASA has historically issued both warrants and options (hereafter referred to as "options") to the Board of Directors, executive management and key employees of the Group under option agreements. In December 2020, the Board of Directors approved the 2020 share option rules (the "2020 Rules") for employees of the Group. The options give the holder the right to purchase Nykode Therapeutics ASA` stock at a specific price. The options have generally been granted in tranches that vest over 0-3 years, with grants under the 2020 Rules vesting over 4 years, subject to employment in the Group.

The options can be exercised on average 4-5 years after the grant date. The Group accounts for the options as equity-settled transactions, measured by applying the Black-Scholes-Merton option-pricing model for European options ("BSM"). Options held by members of the Board of Directors and management at the end of the reporting period are summarized in note 6.1.

The fair value of the options was determined at the grant dates and expensed over the vesting period. For the Group, USD 3.7 million was expensed as employee benefit expenses in the period (USD 3.8 million in 2022). USD 1.6 million was expensed as employment benefit expenses in the period for the Parent Company (USD 2.6 million in 2022). The expected future social security tax on share-based payments are recorded as a liability and disclosed in note 2.7.

Movements during the year

The following table illustrates the number and weighted average exercise prices (WAEP) of, and movements in, share options during the year:

	2023 WAEP (NOK)	2023 Number	2022 WAEP (NOK)	2022 Number
Outstanding options January 1	28.52	10,511,058	18.20	13,507,698
Options granted*	28.19	3,060,287	34.39	2,639,383
Options forfeited	30.26	(316,859)	39.38	(561,123)
Options exercised	9.77	(2,302,735)	3.33	(5,074,900)
Options expired	–	—	–	—
Outstanding options December 31	32.13	10,951,751	28.52	10,511,058
Exercisable at December 31	**25.80**	**5,451,524**	**15.33**	**5,688,153**

* Options granted during 2023 exclude the 2.91 million options granted to the CEO in November 2023 as these are conditional upon the 2.91 million warrants with the same strike price and with expiry date December 31, 2023 held by the CEO not being exercised.

4.7 Share based payments (Continued)

Overview of outstanding options at December 31, 2023:

Exercise price (NOK)	Number of outstanding options	Weighted Average remaining contractual life	Number of options exercisable
0.01	4,674	1.35	4,674
8.80	2,910,000	1.00	2,910,000
25.14	38,853	4.34	—
25.20	478,333	1.42	478,333
25.72	48,329	4.22	—
25.77	123,018	3.81	30,754
26.42	107,328	4.42	—
26.64	153,482	4.75	—
27.87	75,000	2.34	—
28.20	126,406	4.67	—
28.47	2,447,936	4.52	—
29.44	139,086	3.59	34,771
30.50	478,333	1.59	478,333
31.11	302,251	3.50	75,562
31.90	425,000	1.47	291,667
34.99	1,272,794	3.38	328,053
36.72	44,656	3.67	11,164
39.75	84,385	3.34	21,096
61.10	40,000	3.10	10,000
64.70	6,095	2.59	6,095
69.58	177,000	2.09	88,500
70.78	11,250	2.78	11,250
72.82	80,000	2.67	40,000
75.05	47,542	2.75	23,772
76.77	800,000	2.34	400,000
78.10	30,000	3.00	7,500
81.14	200,000	2.43	100,000
100.00	300,000	1.25	100,000
Total outstanding options	**10,951,751**		**5,451,524**

Overview of outstanding options at December 31, 2022:

Exercise price (NOK)	Number of outstanding options	Weighted Average remaining contractual life	Number of options exercisable
0.01	4,674	2.35	4,674
2.50	400,000	0.08	400,000
7.00	133,335	1.00	133,335
8.80	2,910,000	1.00	2,910,000
9.40	1,250,000	1.00	830,000
12.20	200,000	1.00	—
18.00	400,000	0.08	400,000
25.20	500,000	2.42	333,330
25.77	123,018	4.81	—
29.44	139,086	4.59	—
30.50	500,000	2.59	333,333
31.11	302,251	4.50	—
31.90	425,000	2.47	—
34.99	1,369,016	4.38	—
36.72	44,656	4.67	—
39.75	84,385	4.34	—
61.10	40,000	4.10	—
64.70	6,095	3.59	6,095
69.58	177,000	3.09	44,250
70.78	45,000	3.78	11,250
72.82	80,000	3.67	20,000
75.05	47,542	3.75	11,886
76.77	800,000	3.34	200,000
78.10	30,000	4.00	—
81.14	200,000	3.43	50,000
100.00	300,000	2.25	—
Total outstanding options	**10,511,058**		**5,688,153**

4.7 Share based payments (Continued)

SIGNIFICANT ACCOUNTING ESTIMATES AND ASSUMPTIONS
Estimating fair value for share-based payment transactions requires determination of the most appropriate valuation model, which depends on the terms and conditions of the grant. This estimate also requires determination of the most appropriate inputs to the valuation model including the expected life of the options, volatility and dividend yield and making assumptions about them. Due to limited historical data and liquidity these assumptions include significant estimates by management.

Assumptions used to determine fair value of option grants:
The following table lists the inputs to the model used for the plans for the years ended December 31, 2023 and 2022, respectively:

	2023	2022
Weighted average fair values at the measurement date (NOK)	11.36	11.47
Dividend yield (%)	0%	0%
Expected volatility (%)	60.55%	56.62%
Risk–free interest rate (%)	3.99%	2.60%
Expected life of share options (years)	2.49	3.32
Weighted average share price (NOK)	22.63	30.40
Weighted average exercise price (NOK)	18.74	34.39
Model used	**BSM**	**BSM**

The expected life of the options is based on historical data and current expectations and is not necessarily indicative of exercise patterns that may occur. The expected volatility reflects the assumption that the historical volatility over a period similar to the life of the options is indicative of future trends, which may not necessarily be the actual outcome.

4.8 Earnings per share

The following table reflects the income and share data used in the EPS calculations:

Group	2023	2022
Profit or loss attributable to ordinary equity holders - for basic EPS	(35,154)	(42,743)
Profit or loss attributable to ordinary equity holders adjusted for the effect of dilution*	(35,154)	(42,743)
Weighted average number of ordinary shares - for basic EPS	300,520,364	290,118,981
Weighted average number of ordinary shares adjusted for the effect of dilution	300,520,364	290,118,981
Basic EPS - profit or loss attributable to equity holders of the Group	**(0.12)**	**(0.15)**
Diluted EPS - profit or loss attributable to equity holders of the Group*	**(0.12)**	**(0.15)**

Parent	2023	2022
Profit or loss attributable to ordinary equity holders - for basic EPS	(33,392)	(41,680)
Profit or loss attributable to ordinary equity holders adjusted for the effect of dilution*	(33,392)	(41,680)
Weighted average number of ordinary shares - for basic EPS	300,520,364	290,118,981
Weighted average number of ordinary shares adjusted for the effect of dilution	300,520,364	290,118,981
Basic EPS - profit or loss attributable to equity holders of the Parent Company	**(0.11)**	**(0.14)**
Diluted EPS - profit or loss attributable to equity holders of the Parent Company*	**(0.11)**	**(0.14)**

* The ordinary shares are not adjusted for the effect of dilution as the effect of including the additional shares is antidilutive.

Since the Company was in a net loss position for the years ended December 31, 2023 and 2022 there is no difference between the number of shares used to calculate basic and diluted earnings per share. The potential shares of common stock were excluded from the computation of diluted net loss per share attributable to equity holders of the Parent Company for the period presented because including them would have been anti-dilutive are as follows:

	2023	2022
Options and warrants	4,340,144	8,495,206

4.9 Investments in subsidiaries

The following subsidiaries have been included in the financial statements:

Subsidiaries as of December 31, 2023	Established year	Location	Share ownership	Voting Rights
Nykode Therapeutics Denmark A/S	2021	Denmark	100%	100%

All intellectual property (IP) is owned Nykode Therapeutics ASA. Nykode Therapeutics ASA is the ultimate parent company of the Group. All subsidiaries invoice Nykode Therapeutics ASA according to the Group's transfer pricing policy.

Investments in subsidiaries are accounted for at cost.

5.1 Taxes

ACCOUNTING POLICIES

Current income tax

Current income tax is measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted at the reporting date in the countries where the Group operates and generates taxable income. Current income tax relating to items recognized directly in equity is recognized in equity (OCI) and not in the statement of profit or loss.

Deferred tax

Deferred tax is provided using the liability method on temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date. Deferred tax liabilities are recognized for all taxable temporary differences, except:

- When the deferred tax liability arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss
- In respect of taxable temporary differences associated with investments in subsidiaries, associates and interests in joint arrangements, when the timing of the reversal of the temporary differences can be controlled and it is probable that the temporary differences will not reverse in the foreseeable future

Deferred tax assets are recognized to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utilized, except:

- When the deferred tax asset relating to the deductible temporary difference arises from the initial recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction, affects neither the accounting profit nor taxable profit or loss
- In respect of deductible temporary differences associated with investments in subsidiaries, associates and interests in joint arrangements, deferred tax assets are recognized only to the extent that it is probable that the temporary differences will reverse in the foreseeable future and taxable profit will be available against which the temporary differences can be utilized

The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilized.

Unrecognized deferred tax assets are re-assessed at each reporting date and are recognized to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date.

Deferred tax relating to items recognized outside profit or loss is recognized outside profit or loss. Deferred tax items are recognized in correlation to the underlying transaction either in OCI or directly in equity.

Deferred tax assets and deferred tax liabilities are offset if a legally enforceable right exists to set off current tax assets against current tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation authority.

MATERIAL ACCOUNTING JUDGEMENTS, ESTIMATES AND ASSUMPTIONS

Deferred tax assets are recognized for unused tax losses to the extent that it is probable that taxable profit will be available against which the losses can be utilized. Significant management judgement is required to determine the amount of deferred tax assets that can be recognized, based upon the likely timing and the level of future taxable profits, together with future tax planning strategies.

The Group has USD 42.9 million as at December 31, 2023 (USD 16.2 million as at December 31, 2022) of tax losses carried forward. Tax losses carried forward for the Parent Company are USD 42.9 million as at December 31, 2023 (USD 16.2 million as at December 31, 2022). These losses relate to historical losses in the Parent Company. The tax loss carried forward from Norwegian entities may be offset against future taxable income and will not expire.

5.1 Taxes (Continued)

Group

Current income tax expense:	**2023**	**2022**
Income tax payable	103	80
Change deferred tax/deferred tax assets (ex. OCI effects)	(9,035)	(8,321)
Adjustments for current tax of prior periods	—	1
Total income tax expense	**(8,932)**	**(8,240)**

Deferred tax relates to the following:	**12/31/2023**	**12/31/2022**
Property, plant and equipment	651	380
Other current assets	105,146	135,634
Other liabilities	(8,156)	(24,004)
Losses carried forward	(42,888)	(16,198)
Basis for deferred tax	**54,753**	**95,812**
Deferred tax liabilities in the statement of financial position	**12,046**	**21,079**

Reconciliation of income tax expense	**2023**	**2022**
Profit or loss before tax	**(44,086)**	**(50,983)**
Tax expense 22%	(9,699)	(11,216)
Permanent differences	457	406
Currency effects	310	2,570
Recognized income tax expense	**(8,932)**	**(8,240)**

Parent

Current income tax expense:	2023	2022
Income tax payable	—	—
Change deferred tax/deferred tax assets (ex. OCI effects)	(9,037)	(8,320)
Total income tax expense	**(9,037)**	**(8,320)**

Deferred tax relates to the following:	12/31/2023	12/31/2022
Property, plant and equipment	621	380
Other current assets	105,146	135,634
Other liabilities	(8,150)	(24,004)
Losses carried forward	(42,888)	(16,198)
Basis for deferred tax	**54,729**	**95,812**
Deferred tax liabilities in the statement of financial position	**12,040**	**21,079**

The Parent Company's operations are subject to income tax in Norway. The statutory income tax rate is 22% for both periods.

A reconciliation of the differences between the theoretical tax expense under the rate applicable in Norway and the actual tax expense is as follows:

Reconciliation of income tax expense	2023	2022
Profit or loss before tax	**(42,429)**	**(50,000)**
Tax expense 22% (Norwegian tax rate)	(9,334)	(11,000)
Permanent differences	456	406
Currency effects	(159)	2,273
Recognized income tax expense	**(9,037)**	**(8,320)**

6.1 Remuneration to Executive Management and the Board of Directors

Remuneration to the Board of Directors
Remuneration for the members of the Board of Directors is determined by the Annual General Meeting ("AGM"). The remuneration is not linked to the Group's performance but reflects the Board of Director's responsibilities, expertise, time and commitment.

The Board members also receive compensation for their services through options. The conditions for these grants and the terms are determined by the AGM. The Board members holdings of options are summarized further below.

Remuneration to Executive Management
The AGM of Nykode Therapeutics ASA determines the principles applicable to the Group's policy for compensation to the Executive Management team.

Loans and guarantees
No loans have been granted and no guarantees have been issued to the Executive Management or any member of the Board of Directors.

Remuneration to Executive Management for the year ended December 31, 2023:

Name	Salary	Bonus	Pension	Other compensation	Total remuneration
Executive Management	1,829	580	161	4	2,574

Remuneration to Executive Management for the year ended December 31, 2022:

Name	Salary	Bonus	Pension	Other compensation	Total remuneration
Executive Management	1,195	276	105	6	1,581

Remuneration to the Board of Directors:

Name	Title	2023	2022
Martin Nicklasson	Chair of the Board	95	78
Anders Tuv	Board member	60	80
Bernd Robert Seizinger	Board member	53	71
Christian Åbyholm	Board member	50	46
Birgitte Volck	Board member	53	71
Anne Clem Whitaker	Board member	50	25
Elaine Sullivan	Board member	60	30
Harald Arnet	Board member	50	–
Einar Jørgen Greve	Deputy board member and former board member	45	43
Trygve Lauvdal	Observer to the Board and former Board member	–	13
Jan Haudemann-Andersen	Former Board member	–	46
Total compensation to Board of Directors		**516**	**503**

6.1 Remuneration to Executive Management and the Board of Directors (Continued)

Shares held by the Board of Directors:

Name	Title	31.12.2023	31.12.2022
Martin Nicklasson	Chair of the Board	52,000	32,000
Anders Tuv 1)	Board member	325,000	–
Bernd Robert Seizinger	Board member	600,000	600,000
Harald Arnet 2)	Board member	168,000	668,000
Christian Åbyholm3)	Board member	2,155,295	2,105,295
Birgitte Volck	Board member	–	–
Anne Clem Whitaker	Board member	–	–
Elaine Sullivan	Board member	–	–
Einar Jørgen Greve 4)	Deputy Board member and former Board member	1,775,000	1,775,000
Jan Haudemann-Andersen 5)	Former Board member	41,189,050	40,689,050
Total		**46,264,345**	**45,869,345**

1) Shares are held through Tuv Capital AS
2) Shares are held through Hato Invest AS
3) 2,055,295 per December 31, 2023 and 2,005,295 per December 31, 2022 of the share are held through Caaby AS
4) Shares are held through Cipriano AS
5) 40,955,750 per December 31, 2023 and 40,455,750 per December 31, 2022 of the shares are held through Datum Opportunity AS, Datum AS and Datum Finans AS.

Warrants and options held by Executive Management:

Name	31.12.2023	31.12.2022
Warrants and options held by Executive Management	5,664,387	4,837,486
Total	**5,664,387**	**4,837,486**

Warrants and options held by the Board of Directors:

Name	Title	31.12.2023	31.12.2022
Martin Nicklasson	Chair of the Board	525,000	500,000
Anders Tuv	Board member	55,000	845,000
Bernd Robert Seizinger	Board member	55,000	45,000
Harald Arnet	Board member	—	—
Cristian Åbyholm	Board member	—	—
Birgitte Volck	Board member	59,674	49,674
Anne Clem Whitaker	Board member	55,000	45,000
Elaine Sullivan	Board member	55,000	45,000
Einar Jørgen Greve	Deputy Board member and former Board member	—	—
Total		**804,674**	**1,529,674**

6.2 Related party transactions

Related parties are major shareholders, members of the Board of Directors and Executive Management in the Group. Note 4.5 provides information on the major shareholders. Significant agreements and remuneration paid to Executive Management and the Board of Directors for the current and prior period is presented in note 6.1. All transactions with related parties are based on the principle of arm's length.

The payments to related parties consist of salary, bonus, pension, other compensation and board remuneration paid to Executive management and Board members. The Executive management and the Board members also held shares and options in the Parent Company at the end of the period as presented in note 6.1.

The Group had no related party balances at December 31, 2023 or December 31, 2022.

In 2023, the Parent Company has purchased services from subsidiaries for USD 8.8 million (2022: USD 6.6 million) and on December 31, 2023 the parent company had a net payable to its subsidiaries of USD 0.8 million (2022: 0.3 million).

6.3 Events after the reporting period

Adjusting events
There have been no significant adjusting events subsequent to the reporting date.

Non-adjusting events
There have been no significant non-adjusting events subsequent to the reporting date.

7.1 Changes in IFRS and new standards

New and amended IFRS Accounting Standards that are effective for the current year
In the current year, the Group has applied a number of amendments to IFRS Accounting Standards issued by the International Accounting Standards Board (IASB) that are mandatory effective for an accounting period that begins on or after 1 January 2023. Their adoption has not had any material impact on the disclosures or on the amounts reported in these financial statements.

Amendments to IAS 1 Presentation of Financial Statements and IFRS Practice Statement 2 Making Materiality Judgements— Disclosure of Accounting Policies
The group has adopted the amendments to IAS 1 for the first time in the current year. The amendments change the requirements in IAS 1 with regard to disclosure of accounting policies. The amendments replace all instances of the term 'significant accounting policies' with 'material accounting policy information'. Accounting policy information is material if, when considered together with other information included in an entity's financial statements, it can reasonably be expected to influence decisions that the primary users of general purpose financial statements make on the basis of those financial statements. The supporting paragraphs in IAS 1 are also amended to clarify that accounting policy information that relates to immaterial transactions, other events or conditions is immaterial and need not be disclosed. Accounting policy information may be material because of the nature of the related transactions, other events or conditions, even if the amounts are immaterial. However, not all accounting policy information relating to material transactions, other events or conditions is itself material.

The IASB has also developed guidance and examples to explain and demonstrate the application of the 'four-step materiality process' described in IFRS Practice Statement 2.

Amendments to IAS 8 - Accounting policies, Changes in Accounting Estimates and Errors - Definition of Accounting Estimates
The group has adopted the amendments to IAS 8 for the first time in the current year. The amendments replace the definition of a change in accounting estimates with a definition of accounting estimates. Under the new definition, accounting estimates are "monetary amounts in financial statements that are subject to measurement uncertainty". The definition of a change in accounting estimates was deleted.

IFRS 17 Insurance Contracts
IFRS 17 Insurance Contracts is a comprehensive new accounting standard for insurance contracts covering recognition and measurement, presentation and disclosure. IFRS 17 replaces IFRS 4 Insurance Contracts. IFRS 17 applies to all types of insurance contracts (i.e., life, non-life, direct insurance and re-insurance), regardless of the type of entities that issue them as well as to certain guarantees and financial instruments with discretionary participation features; a few scope exceptions will apply. The overall objective of IFRS 17 is to provide a comprehensive accounting model for insurance contracts that is more useful and consistent for insurers, covering all relevant accounting aspects. IFRS 17 is based on a general model, supplemented by:

- A specific adaptation for contracts with direct participation features (the variable fee approach)
- A simplified approach (the premium allocation approach) mainly for short-duration contracts

The new standard had no impact on the Group's consolidated financial statements.

New and revised IFRS Accounting Standards in issue but not yet effective

Amendments to IFRS 16: Lease Liability in a Sale and Leaseback
In September 2022, the IASB issued amendments to IFRS 16 to specify the requirements that a seller-lessee uses in measuring the lease liability arising in a sale and leaseback transaction, to ensure the seller-lessee does not recognise any amount of the gain or loss that relates to the right of use it retains.

The amendments are effective for annual reporting periods beginning on or after 1 January 2024 and must applied retrospectively to sale and leaseback transactions entered into after the date of initial application of IFRS 16. Earlier application is permitted and that fact must be disclosed.

The amendments are not expected to have a material impact on the Group's financial statements.

Amendments to IAS 1: Classification of Liabilities as Current or Non-current
In January 2020 and October 2022, the IASB issued amendments to paragraphs 69 to 76 of IAS 1 to specify the requirements for classifying liabilities as current or non-current. The amendments clarify:

- What is meant by a right to defer settlement
- That a right to defer must exist at the end of the reporting period
- That classification is unaffected by the likelihood that an entity will exercise its deferral right
- That only if an embedded derivative in a convertible liability is itself an equity instrument would the terms of a liability not impact its classification

In addition, a requirement has been introduced to require disclosure when a liability arising from a loan agreement is classified as non-current and the entity's right to defer settlement is contingent on compliance with future covenants within twelve months.

The amendments are not expected to have a material impact on the Group's financial statements.

Supplier Finance Arrangements - Amendments to IAS 7 and IFRS 7
In May 2023, the IASB issued amendments to IAS 7 Statement of Cash Flows and IFRS 7 Financial Instruments: Disclosures to clarify the characteristics of supplier finance arrangements and require additional disclosure of such arrangements. The disclosure requirements in the amendments are intended to assist users of financial statements in understanding the effects of supplier finance arrangements on an entity's liabilities, cash flows and exposure to liquidity risk.

The amendments will be effective for annual reporting periods beginning on or after 1 January 2024. Early adoption is permitted, but will need to be disclosed.

The amendments are not expected to have a material impact on the Group's financial statements.

INDEPENDENT AUDITOR'S REPORT

Deloitte.

To the General Meeting of Nykode Therapeutics ASA

INDEPENDENT AUDITOR'S REPORT

Report on the Audit of the Financial Statements

Opinion
We have audited the financial statements of Nykode Therapeutics ASA, which comprise:

- The financial statements of the parent company Nykode Therapeutics ASA (the Company), which comprise the balance sheet as at 31 December 2023, statement of comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, and notes to the financial statements, including material accounting policy information.
- The consolidated financial statements of Nykode Therapeutics ASA and its subsidiaries (the Group), which comprise the balance sheet as at 31 December 2023, statement of comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, and notes to the financial statements, including material accounting policy information.

In our opinion

- the financial statements comply with applicable statutory requirements,
- the financial statements give a true and fair view of the financial position of the Company as at 31 December 2023, and its financial performance and its cash flows for the year then ended in accordance with IFRS Accounting Standards as adopted by the EU, and
- the consolidated financial statements give a true and fair view of the financial position of the Group as at 31 December 2023, and its financial performance and its cash flows for the year then ended in accordance with IFRS Accounting Standards as adopted by the EU.

Our opinion is consistent with our additional report to the Audit Committee.

Basis for Opinion
We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company and the Group as required by relevant laws and regulations in Norway and the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (including International Independence Standards) (IESBA Code), and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

To the best of our knowledge and belief, no prohibited non-audit services referred to in the Audit Regulation (537/2014) Article 5.1 have been provided.

The Company was listed in June 2022. We were the independent auditor of the Company prior to the listing. We have been the independent auditor of the Company for 2 years after the listing, including the year of listing.

Key Audit Matters
Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of 2023. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

We have determined that there are no key audit matters to communicate in our report.

Other Information
The Board of Directors and the Managing Director (management) are responsible for the information in the Board of Directors' report and the other information accompanying the financial statements. The other information comprises information in the annual report, but does not include the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the information in the Board of Directors' report nor the other information accompanying the financial statements.

In connection with our audit of the financial statements, our responsibility is to read the Board of Directors' report and the other information accompanying the financial statements. The purpose is to consider if there is material inconsistency between the Board of Directors' report and the other information accompanying the financial statements and the financial statements or our knowledge obtained in the audit, or whether the Board of Directors' report and the other information accompanying the financial statements otherwise appear to be materially misstated. We are required to report if there is

Deloitte.

a material misstatement in the Board of Directors' report or the other information accompanying the financial statements. We have nothing to report in this regard.

Based on our knowledge obtained in the audit, it is our opinion that the Board of Directors' report

- is consistent with the financial statements and
- contains the information required by applicable statutory requirements.

Our opinion on the Board of Directors' report applies correspondingly to the statements on Corporate Governance and Corporate Social Responsibility.

Responsibilities of Management for the Financial Statements
Management is responsible for the preparation of financial statements that give a true and fair view in accordance with IFRS Accounting Standards as adopted by the EU, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's and the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or the Group or to cease operations, or has no realistic alternative but to do so.

Auditor's Responsibilities for the Audit of the Financial Statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error. We design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's and the Group's internal control.
- evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- conclude on the appropriateness of management's use of the going concern basis of accounting, and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's and the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company and the Group to cease to continue as a going concern.
- evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves a true and fair view.
- obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

Deloitte.

We communicate with the Board of Directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide the Audit Committee with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with the Board of Directors, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

Report on Compliance with Requirement on European Single Electronic Format (ESEF)

Opinion
As part of the audit of the financial statements of Nykode Therapeutics ASA, we have performed an assurance engagement to obtain reasonable assurance about whether the financial statements included in the annual report, with the file name nykode-2023-12-31-en.zip, have been prepared, in all material respects, in compliance with the requirements of the Commission Delegated Regulation (EU) 2019/815 on the European Single Electronic Format (ESEF Regulation) and regulation pursuant to Section 5-5 of the Norwegian Securities Trading Act, which includes requirements related to the preparation of the annual report in XHTML format and iXBRL tagging of the consolidated financial statements.

In our opinion, the financial statements, included in the annual report, have been prepared, in all material respects, in compliance with the ESEF regulation.

Management's Responsibilities
Management is responsible for the preparation of the annual report in compliance with the ESEF regulation. This responsibility comprises an adequate process and such internal control as management determines is necessary.

Auditor's Responsibilities
Our responsibility, based on audit evidence obtained, is to express an opinion on whether, in all material respects, the financial statements included in the annual report have been prepared in compliance with ESEF. We conduct our work in compliance with the International Standard for Assurance Engagements (ISAE) 3000 – "Assurance engagements other than audits or reviews of historical financial information". The standard requires us to plan and perform procedures to obtain reasonable assurance about whether the financial statements included in the annual report have been prepared in compliance with the ESEF Regulation.

As part of our work, we have performed procedures to obtain an understanding of the Company's processes for preparing the financial statements in compliance with the ESEF Regulation. We examine whether the financial statements are presented in XHTML-format. We evaluate the completeness and accuracy of the iXBRL tagging of the consolidated financial statements and assess management's use of judgement. Our procedures include reconciliation of the iXBRL tagged data with the audited financial statements in human-readable format. We believe that the evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Oslo, 18 April 2024
Deloitte AS

Reidar Ludvigsen
State Authorised Public Accountant

This document is signed electronically.

GLOSSARY

Antigen
An antigen is a molecule recognized by the immune system. "Non-self" antigens are identified as intruders and attacked by the immune system.

APC
Antigen Presenting Cells (APC) are part of the immune system and are cells that display antigens on their surfaces and present them to T cells.

B cell
Immune cells, also known as B lymphocytes, are responsible for mediating the production of antigen-specific antibodies.

CCL3L1
CCL3L1, C-C motif chemokine ligand 3 like 1, a chemokine that attracts APC and ensures binding to receptors on the surface and subsequent internalization into the APCs. It is used as a targeting module in many Vaccibody vaccines.

CD4+ T cells
Also known as helper T cells, CD4+ T cells are immune cells able to activate and help other immune cells by releasing signaling molecules, thereby orchestrating an optimal immune response. Together, CD4+T cells and CD8+T cells comprise the majority of T-lymphocytes.

CD8+ T cells
Immune cells (T lymphocytes) able to kill cancer or virus-infected cells, also known as cytotoxic or killer T cells. CD8+T cells together with CD4+T cells comprise the majority of T-lymphocytes.

Cervical Intraepithelial Neoplasia (CIN)
The abnormal pre-cancerous growth of cells in the uterine cervix usually caused by HPV infection.

Checkpoint inhibitor
Checkpoint inhibitors, also known as immune checkpoint inhibitors, is a type of drug that activates the immune system to fight cancer. The drug prevents the "off" signal, which then enables the immune system to become activated.

CMC
Chemistry, Manufacturing and Controls.

ctDNA
Circulating tumor DNA (ctDNA) is tumor-derived fragmented DNA in the bloodstream coming from dying cancer cells and tumors. Detection of reduced levels of ctDNA may be an early marker of response to cancer treatment.

DNA
Deoxyribonucleic acid (DNA) is the hereditary material found in every cell and is unique for each individual. DNA consists of genes that encode for proteins.

DNA vaccine
Vaccines are made to induce an immune response to an antigen, to boost the immune system. When the antigen is delivered as a DNA molecule (plasmid), it is called a DNA vaccine.

Epitope
An epitope is the part of an antigen that is recognized by the immune system, specifically by antibodies, B cells, or T cells. For example, the epitope is the specific piece of the antigen to which a T cell binds.

First-in-class vaccine
A vaccine that utilizes a new and unique mechanism of action to treat a medical condition.

Human Leukocyte Antigen (HLA) system
Human version of the Major Histocompatibility Complex (MHC) encoding for cell surface proteins responsible for the presentation of intracellular (MHC class I) and extracellular (MHC class II) proteins to the immune system.

HPV
Human papillomavirus. There are several strains, and HPV16 is the strain most associated with cancer.

HSIL
High-grade squamous intraepithelial lesions of the cervix. This corresponds to cervical intraepithelial neoplasia grade 2/3 (CIN 2/3).

Immuno-oncology
Cancer immunotherapy, also called immuno-oncology, is a type of cancer treatment that helps the immune system fight cancer.

Individualized vaccine
On-demand vaccine designed and manufactured specifically for each individual patient.

IP
Intellectual property such as patents and know-how.

mRNA
mRNA, or messenger RNA, is like a blueprint that cells use to build proteins based on instructions from your DNA. It's a crucial part of how your body reads and uses genetic information to function properly.

Mutation
A change or alteration that occurs in the DNA. Mutations may lead to cancer, and these mutations may be identified and recognized by the immune system.

Neoantigen
Novel tumor-specific antigens (TSAs) derived from somatic gene mutations in cancer cells that are solely expressed on a patient's tumor. These mutations may be regarded as truly foreign by the immune system.

NYK011
Nykode Therapeutics' preclinical oncology vaccine program.

Off-the-shelf vaccine
Vaccine that can be manufactured, stored and may be used to treat large patient groups.

Phase I/IIa
Early-phase clinical trials intended to evaluate safety/tolerability and initial clinical effect.

Plasmid
A small DNA molecule carrying genes that can be expressed as proteins within a host cell.

Prophylactic vaccines
Prophylactic vaccines are vaccines that may prevent disease before it occurs, whereas therapeutic vaccines are administered after an individual has already been affected by the disease or infection.

R&D
Research and development.

Regulatory T cell (Treg)
A subpopulation of immunosuppressive T cells maintaining tolerance to self-antigens and regulating the prevention of autoimmune diseases.

RNA
Ribonucleic acid (RNA) is a polymeric molecule essential in various biological roles in coding, decoding, regulation and expression of genes. All of the RNA in a natural cell is made by DNA transcription.

T cell
Immune cells of key importance to the immune system recognizing and fighting specific pathogens or cancer antigens. See also CD4+ T cells and CD8+ T cells.

Tumor-Associated Antigens (TAAs)
Self-antigens with elevated expression in tumor cells.

Vaccibody™ technology platform
A proprietary vaccine delivery platform intended to make more efficacious vaccines by targeting the antigen to APC.

VB10.16
Nykode Therapeutics' off-the-shelf drug candidate targeting HPV16-induced malignancies such as cervical cancer.

VB10.NEO
A Vaccibody individualized drug candidate where each vaccine is designed based on each patient's cancer-specific gene alterations (mutations). VB10.NEO is exclusively licensed to Genentech.

CORPORATE INFORMATION

Nykode Therapeutics ASA
Gaustadalléen 21
0349 Oslo
Norway
Phone: +47 22 95 81 93
E-mail: info@nykode.com
Organization number: N-990 646 066 MVA

www.nykode.com

Commercial bank
Nordea Bank Abp, filial i Norge
Essendrops gate 7
0107 Oslo
Norway

Auditor
Deloitte AS
Dronning Eufemias gate 14
0191 Oslo
Norway

Annual General Meeting
This year's Annual General Meeting to be held on May 16, 2024.



Nykode Therapeutics ASA
Gaustadalléen 21
0349 Oslo
Norway

Phone: +47 22 95 81 93
E-mail: info@nykode.com
Organization number: N-990 646 066 MVA

www.nykode.com

April 2024